幽门螺杆菌CagA/UreB口服减毒沙门氏菌活载体疫苗的研究
|
摘要
幽门螺杆菌(Helicobacter pylori, H. pylori, Hp)广泛存在于人类的胃中,是导致慢性胃炎、胃肠溃疡、胃腺癌等胃肠疾病的主要病原菌,已严重影响着人们的身体健康。尽管国内外采用抗生素三联、四联疗法在治疗H. pylori引起相关的胃炎和胃溃疡等胃肠疾病方面取得了较大成果,但临床发现广谱抗生素的治疗导致幽门螺杆菌耐药菌株不断出现和治愈后复发率居高不下,临床上将很快进入“感染-治愈-复发-再治疗-耐药”的恶性循环,不能彻底解决问题。因此希望通过疫苗免疫奶牛使在牛奶中产生高水平的抗幽门螺杆菌抗体,通过口服该抗体,来预防和治疗H. pylori引起的慢性胃炎、胃肠溃疡等胃肠疾病。因此希望使用安全、高效、使用方便的疫苗来免疫动物产生高浓度抗体或用该疫苗免疫动物使之对幽门螺杆菌产生有效的抵抗力。
本研究首先选取生产后10天健康、无乳腺疾病和生殖器官疾病、体温正常的奶牛14头,随机分为两组：PBS对照组和幽门螺杆菌全菌蛋白免疫注射组,每组7头。用浓度为2×1010cfu/mL的幽门螺杆菌(H. polyri)NCTC11637全菌经超声破碎后与等剂量的完全(不完全)弗氏佐剂充分乳化后分别于0、14、28天三次多点肌肉注射全菌蛋白疫苗,每次4mL,免疫产后泌乳的健康奶牛,对照组每次注射PBS与弗氏佐剂乳化物4mL。每周采血和收集牛奶各一次,离心收集血清,以酶联免疫吸附试验测定血清、乳汁的IgG抗体,同时测量体温,观察发情和采食泌乳等健康情况。研究结果显示经肌注幽门螺杆菌全菌蛋白免疫奶牛后可在血清和乳汁中产生特异性抗体,抗体浓度显著高于对照组(P<0.05),但免疫结束后不久逐渐下降。免疫奶牛的体温、发情和采食泌乳等情况正常。但全菌蛋白疫苗费用高,制作麻烦,注射时阻力大、奶牛反应强烈,且需要多次多点注射。结果表明肌肉注射幽门螺杆菌全菌蛋白疫苗是一个安全、有效的免疫途径。但全菌蛋白疫苗制作麻烦,费用高,注射时奶牛反应大。
因此希望构建更加安全、高效和使用更为方便的疫苗代替幽门螺杆菌全菌蛋白疫苗。考虑到幽门螺杆菌是肠道菌群,通过口服引起胃肠道粘膜免疫是一种可行途径。但口服的蛋白疫苗的制作复杂,提纯麻烦,且时间较长,同时需加相应的免疫佐剂提高免疫原性,在口服过程中蛋白疫苗还容易被胃酸及胃蛋白酶破坏而丧失免疫功能。因此考虑用大肠杆菌或减毒沙门氏菌来作为载体。本实验室多次采用减毒猪霍乱沙门氏菌C500作为载体,安全且免疫效果好,希望构建幽门螺杆菌的减毒猪霍乱沙门菌C500口服活载体疫苗。
本实验选取幽门螺杆菌中已证实具有免疫原性的两个基因：尿素酶B(urease B, UreB)和细胞毒素相关抗原(cytotoxin-associated antigen, CagA)。先采用PCR技术从幽门螺杆菌标准株SS1扩增Hp-UreB和Hp-CagA基因,将其连接至原核表达质粒pYA3493中,使之构建为pYA3493-UreB-CagA重组质粒,经PCR及酶切鉴定后测定其基因序列,并与GenBank中已发表的相关序列的进行同源性分析。重组质粒pYA3493-UreB-CagA电击转入减毒猪霍乱沙门菌C500,培养后筛选阳性菌落,抽提质粒进行PCR及酶切鉴定。表达的UreB-CagA蛋白用SDS-PAGE和Western Blotting进行鉴定。然后将无特定病原菌昆明小鼠分成5组,每组10只,分别为肌肉注射幽门螺杆菌全菌蛋白疫苗和灌胃分别给予含质粒pYA3493-UreB-CagA的减毒沙门氏菌C500(0.2mL,1×1010CFUmL-1)、含空质粒pYA3493的减毒沙门氏菌C500(0.2mL,1×1010CFUmL-1)、减毒沙门氏菌C500(0.2mL,1×1010CFUmL-1)以及PBS (0.2mL)。每周免疫一次,连续五次。第六周后再用活H. pylori SS1(0.2mL,1×1010CFUmL-1)灌胃攻击,每天一次,连续三天。第九周采血后处死实验小鼠,取一半胃粘膜和十二指肠研磨进行细菌培养检查H. pylori在胃肠定植情况,另一半用于组织切片和免疫组化观察胃肠损伤情况和免疫蛋白分泌的情况,同时对重要脏器肝、脾、肺进行组织切片观察损伤情况。实验前和实验后每隔一周或二周采血一次,连续8次,离心分离血清,采用ELISA检测小鼠血清中的抗体水平。检验pYA3493-UreB-CagA减毒猪霍乱沙门菌C500口服疫苗对小鼠的免疫效果和口服疫苗的安全性评价。结果：核苷酸序列测定及同源性分析证实,克隆的Hp-CagA和Hp-UreB基因与GenBank中相关序列的同源性分别为98%和100%(472／480和1134／1134)。重组质粒PYA3493-UreB-CagA转染减毒猪霍乱沙门菌C500,可表达约59kD的UreB-CagA蛋白。全菌蛋白注射组和含质粒pYA3493-UreB-CagA的减毒沙门氏菌C500组的血清中幽门螺杆菌特异抗体滴度显著高于含质粒pYA3493的减毒沙门氏菌C500组、减毒沙门氏菌C500组以及PBS组(P<0.01)。但均未完全保护月=pylori SS1对胃的攻击,五组中胃和十二指肠均有H. pylori SS1的定植。但全菌蛋白注射组和含质粒pYA3493-UreB-CagA的减毒沙门氏菌C500组小鼠胃肠内的菌落数量显著低于含质粒pYA3493的减毒沙门氏菌C500组、减毒沙门氏菌C500组以及PBS组(P<0.01)。免疫组化表明全菌注射组和口服疫苗中胃和十二指肠有明显的抗体存在,且所有组胃、十二指肠、肝、脾以及肺均无明显损伤,也无小鼠死亡。结果表明建立了同时表达Hp-CagA和Hp-UreB基因的减毒猪霍乱沙门菌疫苗株,该口服减毒沙门氏菌载体疫苗有明显的免疫预防效果,而且比较安全,但不能完全抑制幽门螺杆菌在胃和十二指肠中定植。
以上是UreB-CagA双价口服活载体疫苗在小鼠体内的免疫效果,安全有效。体外实验希望通过构建H. pylori的CagA和UreB基因重组真核表达质粒用电击法转染到胃粘膜上皮细胞GES-1后,用幽门螺杆菌SSl攻击转染成功的胃上皮细胞((?)ES-1,观察对细胞凋亡及细胞形态的影响,探讨细胞凋亡机制。
采用PCR技术从幽门螺杆菌标准株SS1中获取CagA部分基因和UreB全长基因与真核表达载体pEGFP-N1相连,构建幽门螺杆菌CagA/UreB真核荧光表达载体pEGFP-N1-CagA-UreB,并用脂质体的方法将质粒pEGFP-N1-UreB-CagA和空质粒pEGFP-N1分别转染到胃粘膜上皮细胞GES-1中,用(3418筛选阳性细胞,用幽门螺杆菌SSl分别处理转染pEGFP-N1-CagA-UreB的细胞、转染pEGFP-N1的细胞以及没转染质粒的细胞。用Annexin V-APC和7-AAD染色后,流式细胞术检测胃上皮细胞GES-1凋亡和死亡的情况,同时透射电镜观察胃上皮细胞GES-1的形态变化。结果发现用脂质体转染质粒到细胞GES-1,转染效率可高达60%以上,500μg G418可对转染细胞进行筛选,筛选后的阳性细胞用幽门螺杆菌处理后,凋亡率要小于空质粒转染的细胞和未转染质粒的细胞,但长时间处理后GES-1细胞均死亡,电镜结果显示细胞凋亡和坏死。结果表明质粒pEGFP-N1-UreB-CagA可转染到胃上皮细胞GES-1在培养细胞内的表达可抵抗幽门螺杆菌SSl对细胞GES-1的破坏,减少细胞凋亡。但用幽门螺杆菌长时间、大剂量处理也会导致细胞凋亡和坏死。这说明尿素酶B和CagA可导致细胞凋亡,但同时也有其他途径参与凋亡过程。
Helicobacter pylori is a gram-negative bacterium, specialized in the colonization of the stomach, and well known as the major gastro-duodenal pathogen of peptic ulcer disease, mucosa-associated lymphoid tissue lymphoma, and gastric cancer. In90%of H. pylori-infected patients treated with antibiotics and strong acid suppressor drug such as proton pump inhibitors, its eradication is successful. However, failure of H. pylori eradication treatment has recently increased due to the proliferation of antibiotic-resistant strains. Artificial passive immunization is one way to against H. pylori, and vaccination against H. pylori is therefore one of the most effective ways to control H. pylori infection and, indeed, administration of oral bacterial antigens can protect mice against H. pylori infection.
To observe the effect of intra-muscular injection with H. pylori NCTC11637on the induction of immunity,14lactating cows were randomly divided into2groups:whole bacterial antigen of H. pylori (2×1010cfu) with Freund's adjuvant and PBS with adjuvant. The immunizations were performed on days0,14and28, and milk and serum samples were taken by at intervals of7days and then centrifugalizated and stored at-20℃until use. Serum and milk samples were collected and the levels of anti-Hp IgG assayed by indirect enzyme-linked immunosorbent assay. The results of ELISA proved that specific IgG in serum and milk increased significantly(P≤0.05). But the levels of anti-Hp IgG in serum increaser quickly than that the milk. The temperature, feed and oestrus have no changing. But the whole bacterial antigen of H.pylori made more trouble, the cows had pain when intra-muscular injected, and had several times vaccination. The intra-muscular injection of whole bacterial antigen with adjuvant can induce systemic immune response, and may be a safe and effective immunization route. But the whole bacterial antigen of H.pylori made more trouble, expensive and trouble in used.
So one other vaccine which been safe, effective and convenient should be constructed. Recombinant H. pylori vaccine comprising a single subunit antigen can only induce immune response with limited protection efficiency. Development of oral vaccine would be a new effective strategy for prevention of H. pylori infection. In this study, the protective effect of H. pylori multicomponent vaccine consisting of UreB and CagA subunit antigens was constructed and investigated in mice.
To develop an attenuated salmonella choleraesuis vaccine strain C500expressing Helicobacter pylori CagA and UreB, and to investigate the effects of the two-valence vaccine consisting of Helicobacter pylori CagA and UreB in preventing H. pylori infection in mice and the safety of vaccine. The Hp-UreB and Hp-CagA gene were amplified by PCR respectively and were cloned into prokaryotic expression plasmid pYA3493to construct recombinant plasmid pYA3493-UreB-CagA. The pYA3493-UreB-CagA was performed successively by PCR, enzyme digestion analysis and sequencing. The homology was compared between the cloned Hp-CagA and Hp-UreB gene and related genes in GenBank. The plasmid pYA3493-UreB-CagA was purified and transformed into Salmonella choleraesuis C500strain by electroporation. After be cultivated, positive colonies were picked out and the plasmid was amplified by PCR and enzyme digestion analysis again. The expression of pYA3493-UreB-CagA protein in the C500bacteria was proved by SDS-PAGE and Western Blotting.50Kunming mice were randomly divided into5groups:inoculated orally0.2mL (1×1010CFUmL-1) of C500expressing PYA3493-UreB-CagA, C500with pYA3493, C500, PBS and injection0.2mL (2×109) of H, pylori SS1with adjuvant. Oral doses of1×1010CFUmL-1were administered via an intragastric gavage. Immunizations were performed on days0,7,14,21and28, and serum samples were taken by at intervals of7days or14days. Vaccinated mice were challenged with0.2mL (2×109) H. pylori SSI instilled into stomach one time every day for three days after vaccination in6th week.The immune response was assessed by mice immunity IgG ELISA, Immunohistochemistry and Helicobacter pylori SSl attacking. The safety of vaccine was assessed by the hematoxylin-eosin staining.
The results show the equencing and homologous analysis showed that the homology between the cloned Hp-CagA and Hp-UreB gene and related genes in GenBank reached98%(472/480) and100%(1134/1134) respectively for their nucleotide and deduced amino acid sequences. The expression of UreB-CagA protein could be detected in the culture fluid of C500bacteria. Noticeable IgG response was induced in the sera of mice orally immunized with the Salmonella choleraesuis C500strain consisting of UreB and CagA subunit antigens. Mice vaccinated orally were significantly protected against gastric helicobacter infection following a challenge with Helicobacter pylori strain SSI and the liver, lung, spleen, duodenum and pylorus had no lesions. The immunohistochemical analysis showed that the anti-UreB antibody was positively expressed in both the duodenum and pylorus in immunized orally with C500that expresses the UreB-CagA protein. On the contrary, there was no positive reaction in control groups.
The results showed that the attenuated salmonella choleraesuis strain C500has been established successfully, which lays the foundation for further developing oral H. pylori vaccine. The orally vaccination with expressing UreB-CagA could prevent gastric infection with helicobacter pylori and safe. But didn't against the helicobacter pylori infection completely.
Experiment in vivo showed the orally vaccination with expressing UreB-CagA could prevent gastric infection with helicobacter pylori and safe. But effective in vitro has not been reported.
To investigate the effect of helicobacter pylori on apoptosis of the GES-l transfected pEGFP-N1-UreB-CagA eukaryotic expression plasmid in vitro, the Hp-UreB and Hp-CagA gene were amplified by PCR respectively and were cloned into eukaryotic expression plasmid pEGFP-NI to construct recombinant plasmid pEGFP-NI-UreB-CagA and transfected into GES-1cells and choiced by G418. GES-1cells transfected into plasmid pEGFP-NI-UreB-CagA were cocultured with H. pylori strain SSI and its apoptosis was quantified by flow cytometry using Annexin V-APC and AAD. The recombinant PEGFP-N1-UreB-CagA was constructed and stable transfected into GES-1cells. The apoptotic rates of cells transfected into pEGFP-N1-UreB-CagA plasmids were significantly lower than those of control cells (P<0.01). The GES-1cells were died when H. pylori strain SS1cocultured with cells for a long time.The results showed that the GES-1cells which transfected into pEGFP-Nl-UreB-CagA plasmids can block apoptisis of GES-1cells. But helicobacter pylori also caused cell necrosis for a long time and high dose.
本研究首先选取生产后10天健康、无乳腺疾病和生殖器官疾病、体温正常的奶牛14头,随机分为两组：PBS对照组和幽门螺杆菌全菌蛋白免疫注射组,每组7头。用浓度为2×1010cfu/mL的幽门螺杆菌(H. polyri)NCTC11637全菌经超声破碎后与等剂量的完全(不完全)弗氏佐剂充分乳化后分别于0、14、28天三次多点肌肉注射全菌蛋白疫苗,每次4mL,免疫产后泌乳的健康奶牛,对照组每次注射PBS与弗氏佐剂乳化物4mL。每周采血和收集牛奶各一次,离心收集血清,以酶联免疫吸附试验测定血清、乳汁的IgG抗体,同时测量体温,观察发情和采食泌乳等健康情况。研究结果显示经肌注幽门螺杆菌全菌蛋白免疫奶牛后可在血清和乳汁中产生特异性抗体,抗体浓度显著高于对照组(P<0.05),但免疫结束后不久逐渐下降。免疫奶牛的体温、发情和采食泌乳等情况正常。但全菌蛋白疫苗费用高,制作麻烦,注射时阻力大、奶牛反应强烈,且需要多次多点注射。结果表明肌肉注射幽门螺杆菌全菌蛋白疫苗是一个安全、有效的免疫途径。但全菌蛋白疫苗制作麻烦,费用高,注射时奶牛反应大。
因此希望构建更加安全、高效和使用更为方便的疫苗代替幽门螺杆菌全菌蛋白疫苗。考虑到幽门螺杆菌是肠道菌群,通过口服引起胃肠道粘膜免疫是一种可行途径。但口服的蛋白疫苗的制作复杂,提纯麻烦,且时间较长,同时需加相应的免疫佐剂提高免疫原性,在口服过程中蛋白疫苗还容易被胃酸及胃蛋白酶破坏而丧失免疫功能。因此考虑用大肠杆菌或减毒沙门氏菌来作为载体。本实验室多次采用减毒猪霍乱沙门氏菌C500作为载体,安全且免疫效果好,希望构建幽门螺杆菌的减毒猪霍乱沙门菌C500口服活载体疫苗。
本实验选取幽门螺杆菌中已证实具有免疫原性的两个基因：尿素酶B(urease B, UreB)和细胞毒素相关抗原(cytotoxin-associated antigen, CagA)。先采用PCR技术从幽门螺杆菌标准株SS1扩增Hp-UreB和Hp-CagA基因,将其连接至原核表达质粒pYA3493中,使之构建为pYA3493-UreB-CagA重组质粒,经PCR及酶切鉴定后测定其基因序列,并与GenBank中已发表的相关序列的进行同源性分析。重组质粒pYA3493-UreB-CagA电击转入减毒猪霍乱沙门菌C500,培养后筛选阳性菌落,抽提质粒进行PCR及酶切鉴定。表达的UreB-CagA蛋白用SDS-PAGE和Western Blotting进行鉴定。然后将无特定病原菌昆明小鼠分成5组,每组10只,分别为肌肉注射幽门螺杆菌全菌蛋白疫苗和灌胃分别给予含质粒pYA3493-UreB-CagA的减毒沙门氏菌C500(0.2mL,1×1010CFUmL-1)、含空质粒pYA3493的减毒沙门氏菌C500(0.2mL,1×1010CFUmL-1)、减毒沙门氏菌C500(0.2mL,1×1010CFUmL-1)以及PBS (0.2mL)。每周免疫一次,连续五次。第六周后再用活H. pylori SS1(0.2mL,1×1010CFUmL-1)灌胃攻击,每天一次,连续三天。第九周采血后处死实验小鼠,取一半胃粘膜和十二指肠研磨进行细菌培养检查H. pylori在胃肠定植情况,另一半用于组织切片和免疫组化观察胃肠损伤情况和免疫蛋白分泌的情况,同时对重要脏器肝、脾、肺进行组织切片观察损伤情况。实验前和实验后每隔一周或二周采血一次,连续8次,离心分离血清,采用ELISA检测小鼠血清中的抗体水平。检验pYA3493-UreB-CagA减毒猪霍乱沙门菌C500口服疫苗对小鼠的免疫效果和口服疫苗的安全性评价。结果：核苷酸序列测定及同源性分析证实,克隆的Hp-CagA和Hp-UreB基因与GenBank中相关序列的同源性分别为98%和100%(472／480和1134／1134)。重组质粒PYA3493-UreB-CagA转染减毒猪霍乱沙门菌C500,可表达约59kD的UreB-CagA蛋白。全菌蛋白注射组和含质粒pYA3493-UreB-CagA的减毒沙门氏菌C500组的血清中幽门螺杆菌特异抗体滴度显著高于含质粒pYA3493的减毒沙门氏菌C500组、减毒沙门氏菌C500组以及PBS组(P<0.01)。但均未完全保护月=pylori SS1对胃的攻击,五组中胃和十二指肠均有H. pylori SS1的定植。但全菌蛋白注射组和含质粒pYA3493-UreB-CagA的减毒沙门氏菌C500组小鼠胃肠内的菌落数量显著低于含质粒pYA3493的减毒沙门氏菌C500组、减毒沙门氏菌C500组以及PBS组(P<0.01)。免疫组化表明全菌注射组和口服疫苗中胃和十二指肠有明显的抗体存在,且所有组胃、十二指肠、肝、脾以及肺均无明显损伤,也无小鼠死亡。结果表明建立了同时表达Hp-CagA和Hp-UreB基因的减毒猪霍乱沙门菌疫苗株,该口服减毒沙门氏菌载体疫苗有明显的免疫预防效果,而且比较安全,但不能完全抑制幽门螺杆菌在胃和十二指肠中定植。
以上是UreB-CagA双价口服活载体疫苗在小鼠体内的免疫效果,安全有效。体外实验希望通过构建H. pylori的CagA和UreB基因重组真核表达质粒用电击法转染到胃粘膜上皮细胞GES-1后,用幽门螺杆菌SSl攻击转染成功的胃上皮细胞((?)ES-1,观察对细胞凋亡及细胞形态的影响,探讨细胞凋亡机制。
采用PCR技术从幽门螺杆菌标准株SS1中获取CagA部分基因和UreB全长基因与真核表达载体pEGFP-N1相连,构建幽门螺杆菌CagA/UreB真核荧光表达载体pEGFP-N1-CagA-UreB,并用脂质体的方法将质粒pEGFP-N1-UreB-CagA和空质粒pEGFP-N1分别转染到胃粘膜上皮细胞GES-1中,用(3418筛选阳性细胞,用幽门螺杆菌SSl分别处理转染pEGFP-N1-CagA-UreB的细胞、转染pEGFP-N1的细胞以及没转染质粒的细胞。用Annexin V-APC和7-AAD染色后,流式细胞术检测胃上皮细胞GES-1凋亡和死亡的情况,同时透射电镜观察胃上皮细胞GES-1的形态变化。结果发现用脂质体转染质粒到细胞GES-1,转染效率可高达60%以上,500μg G418可对转染细胞进行筛选,筛选后的阳性细胞用幽门螺杆菌处理后,凋亡率要小于空质粒转染的细胞和未转染质粒的细胞,但长时间处理后GES-1细胞均死亡,电镜结果显示细胞凋亡和坏死。结果表明质粒pEGFP-N1-UreB-CagA可转染到胃上皮细胞GES-1在培养细胞内的表达可抵抗幽门螺杆菌SSl对细胞GES-1的破坏,减少细胞凋亡。但用幽门螺杆菌长时间、大剂量处理也会导致细胞凋亡和坏死。这说明尿素酶B和CagA可导致细胞凋亡,但同时也有其他途径参与凋亡过程。
Helicobacter pylori is a gram-negative bacterium, specialized in the colonization of the stomach, and well known as the major gastro-duodenal pathogen of peptic ulcer disease, mucosa-associated lymphoid tissue lymphoma, and gastric cancer. In90%of H. pylori-infected patients treated with antibiotics and strong acid suppressor drug such as proton pump inhibitors, its eradication is successful. However, failure of H. pylori eradication treatment has recently increased due to the proliferation of antibiotic-resistant strains. Artificial passive immunization is one way to against H. pylori, and vaccination against H. pylori is therefore one of the most effective ways to control H. pylori infection and, indeed, administration of oral bacterial antigens can protect mice against H. pylori infection.
To observe the effect of intra-muscular injection with H. pylori NCTC11637on the induction of immunity,14lactating cows were randomly divided into2groups:whole bacterial antigen of H. pylori (2×1010cfu) with Freund's adjuvant and PBS with adjuvant. The immunizations were performed on days0,14and28, and milk and serum samples were taken by at intervals of7days and then centrifugalizated and stored at-20℃until use. Serum and milk samples were collected and the levels of anti-Hp IgG assayed by indirect enzyme-linked immunosorbent assay. The results of ELISA proved that specific IgG in serum and milk increased significantly(P≤0.05). But the levels of anti-Hp IgG in serum increaser quickly than that the milk. The temperature, feed and oestrus have no changing. But the whole bacterial antigen of H.pylori made more trouble, the cows had pain when intra-muscular injected, and had several times vaccination. The intra-muscular injection of whole bacterial antigen with adjuvant can induce systemic immune response, and may be a safe and effective immunization route. But the whole bacterial antigen of H.pylori made more trouble, expensive and trouble in used.
So one other vaccine which been safe, effective and convenient should be constructed. Recombinant H. pylori vaccine comprising a single subunit antigen can only induce immune response with limited protection efficiency. Development of oral vaccine would be a new effective strategy for prevention of H. pylori infection. In this study, the protective effect of H. pylori multicomponent vaccine consisting of UreB and CagA subunit antigens was constructed and investigated in mice.
To develop an attenuated salmonella choleraesuis vaccine strain C500expressing Helicobacter pylori CagA and UreB, and to investigate the effects of the two-valence vaccine consisting of Helicobacter pylori CagA and UreB in preventing H. pylori infection in mice and the safety of vaccine. The Hp-UreB and Hp-CagA gene were amplified by PCR respectively and were cloned into prokaryotic expression plasmid pYA3493to construct recombinant plasmid pYA3493-UreB-CagA. The pYA3493-UreB-CagA was performed successively by PCR, enzyme digestion analysis and sequencing. The homology was compared between the cloned Hp-CagA and Hp-UreB gene and related genes in GenBank. The plasmid pYA3493-UreB-CagA was purified and transformed into Salmonella choleraesuis C500strain by electroporation. After be cultivated, positive colonies were picked out and the plasmid was amplified by PCR and enzyme digestion analysis again. The expression of pYA3493-UreB-CagA protein in the C500bacteria was proved by SDS-PAGE and Western Blotting.50Kunming mice were randomly divided into5groups:inoculated orally0.2mL (1×1010CFUmL-1) of C500expressing PYA3493-UreB-CagA, C500with pYA3493, C500, PBS and injection0.2mL (2×109) of H, pylori SS1with adjuvant. Oral doses of1×1010CFUmL-1were administered via an intragastric gavage. Immunizations were performed on days0,7,14,21and28, and serum samples were taken by at intervals of7days or14days. Vaccinated mice were challenged with0.2mL (2×109) H. pylori SSI instilled into stomach one time every day for three days after vaccination in6th week.The immune response was assessed by mice immunity IgG ELISA, Immunohistochemistry and Helicobacter pylori SSl attacking. The safety of vaccine was assessed by the hematoxylin-eosin staining.
The results show the equencing and homologous analysis showed that the homology between the cloned Hp-CagA and Hp-UreB gene and related genes in GenBank reached98%(472/480) and100%(1134/1134) respectively for their nucleotide and deduced amino acid sequences. The expression of UreB-CagA protein could be detected in the culture fluid of C500bacteria. Noticeable IgG response was induced in the sera of mice orally immunized with the Salmonella choleraesuis C500strain consisting of UreB and CagA subunit antigens. Mice vaccinated orally were significantly protected against gastric helicobacter infection following a challenge with Helicobacter pylori strain SSI and the liver, lung, spleen, duodenum and pylorus had no lesions. The immunohistochemical analysis showed that the anti-UreB antibody was positively expressed in both the duodenum and pylorus in immunized orally with C500that expresses the UreB-CagA protein. On the contrary, there was no positive reaction in control groups.
The results showed that the attenuated salmonella choleraesuis strain C500has been established successfully, which lays the foundation for further developing oral H. pylori vaccine. The orally vaccination with expressing UreB-CagA could prevent gastric infection with helicobacter pylori and safe. But didn't against the helicobacter pylori infection completely.
Experiment in vivo showed the orally vaccination with expressing UreB-CagA could prevent gastric infection with helicobacter pylori and safe. But effective in vitro has not been reported.
To investigate the effect of helicobacter pylori on apoptosis of the GES-l transfected pEGFP-N1-UreB-CagA eukaryotic expression plasmid in vitro, the Hp-UreB and Hp-CagA gene were amplified by PCR respectively and were cloned into eukaryotic expression plasmid pEGFP-NI to construct recombinant plasmid pEGFP-NI-UreB-CagA and transfected into GES-1cells and choiced by G418. GES-1cells transfected into plasmid pEGFP-NI-UreB-CagA were cocultured with H. pylori strain SSI and its apoptosis was quantified by flow cytometry using Annexin V-APC and AAD. The recombinant PEGFP-N1-UreB-CagA was constructed and stable transfected into GES-1cells. The apoptotic rates of cells transfected into pEGFP-N1-UreB-CagA plasmids were significantly lower than those of control cells (P<0.01). The GES-1cells were died when H. pylori strain SS1cocultured with cells for a long time.The results showed that the GES-1cells which transfected into pEGFP-Nl-UreB-CagA plasmids can block apoptisis of GES-1cells. But helicobacter pylori also caused cell necrosis for a long time and high dose.
引文
1 白杨,王继德,陈烨,林焕建,张兆山,张亚历.幽门螺杆菌黏附素babA2的克隆表达及定位[J].第四军医大学学报,2004,25(2)：128-131.
2 北京地区幽门螺杆菌多中心临床试验协作组.不同组合的三联疗法对幽门螺杆菌阳性十二指肠溃疡的疗效及1年随访研究.中华医学杂志,2004,84(14)：1161-1165.
3 边专,樊明文,杜民权,张平,陈文霞,王茜.变形链球菌Gtase高表达株免疫奶牛应用研究.口腔医学纵横杂志,1999,15(1)：1-3.
4 陈洁,陈星湖,王锦辉,朱森林.幽门螺杆菌疫苗接种小鼠产生免疫后胃炎的影响因素。世界华人消化杂志2006；14(23)：2275～2280
5 陈晶晶,杨昭徐,蒋秀高,张建中,梁丕霞.幽门螺杆菌全菌抗原与尿素酶纯化抗原ELISA检测在人群血清学诊断中的应用.中华流行病学杂志,1996,17(1)：4-6.
6 陈学军,严杰,毛亚飞,李立伟.浙江人群幽门螺杆菌CagA/VacA优势基因型和不同基因型混合感染的调查.中华流行病学杂志,2003(11)：1031-1035.
7 邓长生,杨艺.幽门螺杆菌对胃上皮细胞SGC-901凋亡的影响.中国病理生理杂志,2001,17(12)：1249-1251.
8 丁力。幽门螺杆菌基因克隆及表达。硕士论文,2005.
9 冯百岁,姚雪华,赵国强.幽门螺杆菌细胞毒素相关基因A绿色荧光蛋白真核表达载体的构建.中华医学杂志.2007,(8)：32-36.
10高东旗,李仕英,王庭桂.含抗幽门螺杆菌特异性抗体免疫牛奶的制备.医学动物防制,2005,1：1-2
11高原,邹全明,吴超.幽门螺杆菌napA基因克隆及高效表达与鉴定.中国人兽共患病学报,2006,22(9)：882-887.
12宫月华,袁媛.中国庄河胃癌高发区幽门螺杆菌毒力基因型菌株感染分布特征 [J].中华医学杂志,2006,86(6)：419-421.
13郭红,邹全明,赵晓曼,吴超,毛旭虎,文国义.人幽门螺杆菌热休克蛋白A基因的克隆、表达及初步应用.第三军医大学学报,2001,23(7)：786-789.
14黄昌炳,冯文达,薛民权,张绪基,杨少章,杨绍钧,窦荫梅,贾顺庚.仔猪副伤寒弱毒通气培养冻干苗口服免疫研究[J].中国农业科学,1981,6(1)：89-94.
15黄学勇,许汴利,段广才,范清堂,郗园林.幽门螺杆菌黏附素HpaA蛋白在大肠杆菌中表达及其免疫保护作用.中国人兽共患病学报,2010,26(6)：565-568.
16贾继辉,贾继龙,娄峥,黄谷良,林特夫.幽门螺杆菌L型分子生物字性状的研究.中华微生物学和免疫学杂志,1995,15(2)：95-98.
17康凯.仔猪副伤寒活疫苗[J].中国兽药杂志,2003,37(2)：49.
18兰春慧,张渊智,房殿春.幽门螺杆菌感染诱发蒙古沙鼠胃黏膜肠上皮化生和异型增生[J].解放军医学杂志,2003,28(11)：985-990。
19李仕英,时兰春,王缚鲲,张海谱.含抗幽门螺杆菌特异性抗体牛奶清除效果的动物实验研究.中华医院感染学杂志,2010,20(9)：1230-1232.
20李仕英,王苋,侯雨丰,高东旗,张海谱,赵伟,王宪灵,姚瑶,王庭桂.免疫球蛋白在胃液中对幽门螺杆菌的杀灭作用[J].中国人兽共患病杂志,2004,20(8)：719.
21梁爱心,冯细钢,韩丽,滑国华,桑雷,刘兴斌,刘耘,杨利国.新型生长抑素原核表达质粒的构建及表达鉴定.生物工程学报,2008,24(6)：995-998.
22廖文俊,陈旻湖,朱森林,陈洁,陈为,胡品津.表达幽门螺杆菌过氧化氢酶的减毒沙门氏菌疫苗株的构建及其免疫保护作用的观察,中华医学杂志,2001,10：613-616.
23刘淼,杨致邦,林珊珊,吴利先.幽门螺杆菌细胞空泡毒素基因毒性片段的克隆与表达.重庆医科大学学报,2003,6：720-723.
24刘庆春,韩梅娇,李鸿滨.胃癌与幽门螺杆菌cagA,hrgA基因相关性研究[J].现代生物学进展,2007(2)：261-263.
25刘文忠.幽门螺杆菌研究进展.上海：上海科学技术文献出版社,2001,309-328.
26卢世云,潘秀珍,彭孝伟,施作霖.幽门螺杆菌感染对胃癌细胞的动力学影响[J].世界华人消化杂志,1997,7：760-762.
27潘春留,闰雷,娜仁图娜拉,卿素珠,关伟军,马月辉.流式细胞术研究细胞凋亡的方法与技术.现代生物医学进展,2009,9(4)：790-793.
28庞莎莎,刘丽华.抗幽门螺杆菌免疫抗体口服液清除幽门螺杆菌临床观察.中国中医药信息杂志,1999,6(7)：44.
29乔文,胡家露,吴开春,彭道荣,孙怡群.幽门螺杆菌vacA基因型与胃癌及癌前病变的相关性[J].中华内科杂志,2000,39(11)：729-731.
30任莉,郭刚,邹全明.幽门螺杆菌基因组多态性的研究进展[J].医学研究生学报,2010,23(4)：408-411.
31孙红斌,许杨,熊勇华.特异性抗体对幽门螺杆菌抗原各组分中和作用的初探.第三届国际天然药与微生态学术研讨会论文集.呼合浩特：内蒙古大学出版社,2000： 28.
32谭宝.幽门螺杆菌相关性胃病保健型免疫乳制品制备的研究.硕士毕业论文：2007.
33王娟,王润.中国幽门螺杆菌感染流行病学杂志Mata分析.中华流行病学杂志,2003,24(6)：443-446.
34魏华,许杨,熊勇华.抗幽门螺杆菌牛初乳体外调理杀伤研究.中华微生物学和免疫学杂志.2002,22(2)：168-169.
35吴超,邹全明,郭红,张卫军,袁小澎,毛旭虎.幽门螺杆菌UreB与大肠杆菌LTB基因融合及表达的研究.中华微生物学和免疫学杂志,2002,22(2)：175-179.
36项兆英,Covaeei A, Telford JL, ACensini S, Bayeli PF, Figura N, Rappuoli R.一种新的幽门螺杆菌分类法—根据幽门螺杆菌毒力因子CagA和VacA的表达.中华消化杂志,1995,S1：5-8.
37徐华洲,石玉娥,刘改芳,崔艳,刘文泰,郝慧泉,李国川.抗幽门螺杆菌羊奶的制备及体内外对幽门螺杆菌作用的研究.中国人兽共患病杂志,2003,19(3)： 101-103.
38徐义辉,糜克永,龙焱华.幽门螺杆菌CagA基因探针的制备与临床应用.中华微生物学和免疫学杂志.1999年,3(19)：23-28.
39徐引弟,郭爱珍,刘维红,贾爱卿,陈焕春.猪霍乱沙门氏菌C500株△crp△asd缺失株平衡致死载体系统的构建及鉴定[J].生物工程学报,2006,22(3)：366-372.
40徐引弟,郭爱珍,刘维红,贾爱卿,陈焕春.绿荧光蛋白基因在猪霍乱沙门氏菌C500株asd-缺失株平衡致死载体系统中的表达[J].中国兽医学报,2007,27(4)：493-496.
41许杨,熊勇华,魏华,钟青萍,陈红兵,孙红斌.幽门螺杆菌全菌抗原对母鸡的免疫原性.中国生物制品学杂志,2000,13：147-150.
42阎小君,张沥,韩锋产,江梅,苏成芝.定量检测幽门螺杆菌细胞毒素相关蛋白基因A方法的建立.胃肠病学,1997,3：187-190.
43杨廷彬,尹学念主编.实用免疫学.长春：长春出版社,1994：87.
44杨艺,邓长生.幽门螺杆菌黏附于人胃黏膜的机制.国外医学.消化系疾病分册2000,20：79-82.
45袁小澎,邹全明,柏杨,杨瑁,郭鹰,张卫军,刘正祥.幽门螺杆菌尿素酶B亚单位功能片段的纯化及活性研究.南方医科大学学报,2007；27(7)：959-962.
46张彩凤,夏永华,韩宇,常廷民.幽门螺杆菌iceA基因型与胃黏膜病变的相关性[J].世界华人消化杂志,2008,16(20)：2312-2315.
47张和平,关红,李立民,骆承庠.初乳中低分子量部分的抗炎活性[J].中国乳品工业,2000,28(1)：23-25.
48张和平,李立民,程涛,骆承庠.利用超滤法从免疫初乳中分离乳抗体[J].中国乳品工业,1999,27(4)：3-6.
49张和平,殷文政,王和平,韩润林,李立民,孙天松.免疫乳及其制品研究[J].中国乳品工业,1997,25(5)：15-22.
50张和平,孙天竹,郭军,李立民.免疫初乳中1gG对小鼠腹泻的被动免疫保护[Z]. 哈尔滨：食品科技研究进展,中国畜产品加工研究会,1999：31-38.
51张世联,刘冉,王薇.牛幽门螺杆菌抗体中和菌体蛋白对Hela细胞的生长抑制作用.世界华人消化杂志,2005,15：1828-1833.
52张天哲,袁聚祥,徐应军,张铁民,范红敏,马立人,张小平.幽门螺杆菌免疫奶羊的免疫应答机制及其应用前景分析.卫生研究,2005,34(1)：82-84.
53赵战勤,徐引弟,吴斌,程相朝,李银聚,汤细彪,张春杰,陈焕春.猪霍乱沙门氏菌AasdC500株的生物学特性及作为活疫苗表达载体的应用.生物工程学报,2009,1：29-36.
54甄艳红,韩丽,梁爱心,王庆玲,杨利国.含抑制素重组质粒的减毒猪霍乱沙门氏菌C500遗传稳定性研究[J].生物技术通报,2009(S 1)：300-304.
55周燕,朱尤庆,黄梅芳,肖建群,邓长生.Hp-CagA抗体测定与消化性溃疡和慢性胃炎的关系.武汉大学学报(医学版),2001,22(4)：362-363.
56朱森林,陈旻湖,廖文俊,陈洁,胡品津.表达幽门螺杆菌UreB减毒鼠伤寒沙门氏菌对小鼠的免疫保护作用.中山医科大学学报,2001,22(6)：418-422.
57庄坤,张军,张玲霞,张沥,张建中.西安地区幽门螺杆菌iceAl、iceA2和babA2基因型与致病性的研究[J].细胞与分子免疫学志,2007,23(6)：520-522.
58庄小强,林三仁.幽门螺杆菌与胃癌的研究进展[J].世界华人消化杂志,2000,8：206-207.
59宗红,李建生,张金平,陈香宇,董子明.幽门螺杆菌对胃上皮细胞株GES-1凋亡及XIAP表达的影响.山东医药,2005,45(31)：11-12.
60邹全明,毛旭虎,郭刚,鲁东水,童文德,曾明,王斌,计国欣,朱凤才,李亮.口服重组幽门螺杆菌疫苗Ⅰ、Ⅱ期临床研究.中华医学会第七次全国消化病学术会议论文汇编(上册),2007：285-286.
61 Alm RA, Ling LS, Morr DT, King BL, Brown ED, Doig PC, Smith DR, Noonan B, Guild BC, deJonge BL, Carmel G, Tummino PJ, Caruso A, Uria-Nickelsen M,Mills DM, Ives C, Gibson R, Merberg D, Mills SD, Jiang Q, Taylor DE,Vovis GF, Trust TJ. Genomic sequence comparison of two unrelated isolates of the human gastric pathogen Helicobacter pylori [J]. Nature,1999,397(6715):176-180.
62 Ameiss K, Ashraf S, Kong W, Andrew Pekosz, Wai-Hong Wu, David Milich, Jean-Noel Billaud, Roy Curtiss. Delivery of woodchuck hepatitis virus-like particle presented influenza M2e by recombinant attenuated Salmonella displaying a delayed lysis phenotype[J]. Vaccine,2010,28(41):6704-6713.
63 Ando T, Wassenaar TM, Peek RM Jr, Aras RA, Tschumi AI, van Doom LJ, Kusugami K, Blaser MJ. A Helicobacter pylori restrition endonuclease replacing gene, hrgA is associated with gastric cancer in Asian strain [J]. Cancer Res,2002,62(8): 2385-2389.
64 Atherton JC, Peek RM, Tham KT, Cover TL, Blaser MJ. Clinical and pathological important of heterogeneity in vac A, the vacuolating cytotoxin gene of Helicobacter pylori [J]. Gastroenterology,1997,112 (1):92-99.
65 Backert S, Ziska E, Brinkmann V, Zimny-Arndt U, Fauconnier A, Jungblut PR, Naumann M, Meyer TF. Translocation of the Helicobacter pylori CagA protein in gastric epithelial cells by a type IV secretion apparatus.Cell Microbiol,2000,2: 155-164.
66 Bai Y. Study on the cloning, expression and the immunogenicity of Helicobacter pylori heat shock protein 60 gene [J].Di Yi Jun Yi Da Xue Xue Bao,2002,22(1):3-5.
67 Basso D, Zambon CF, Letley DP, Stranges A, Marchet A, Rhead JL, Schiavon S, Guariso G, Ceroti M, Nitti D, Rugge M, Plebani M, Atherton JC. Clinical relevance of Helicobacter pylori CagA and Vac A gene polymorphisms [J].Gastroenterology, 2008,135(1):91-99.
68 Bumann D, Metzger WG, Mansouri E, Palme O, Wendland M, Hurwitz R, Haas G, Aebischer T, von Specht BU, Meyer TF. Safety and immunogenicity of live recombinant Salmonella enterica serovar Typhi Ty21a expressing urease A and B from Helicobacter pylori in human volunteers.Vaccine,2001,20:845-852.
69 Casella G, Buda CA, Maisano R, Schiavo M, Perego D, Baldini V. Complete regression of primary gastric MALT-lymphoma after double eradication Helicobacter pylori therapy:role and importance of endoscopic ultrasonography. Anticancer Res, 2001,21(2B):1499-1502.
70 Chen GS, Sordillo EM, Ramey WG, Reidy J, Holt PR, Krajewski S, Reed JC, Blaser MJ, Moss SF. Apoptosis in gastric epithelial cell is induced by Helicobacter pylori and accompanied by increased expression of BAK [J]. Biochem Biophys Res Comm, 1997,239 (2):626-632.
71 Chen Y, Wang J, Shi L. In vitro study of the biological activities and immunogenicity of recombinant adhesin of Heliobacter pylori rHpaA. Zhonghua Yixue Zazhi.2000, 81:276-279.
72 Christian P, Nadia H, Perta V. Helicobacter pylori virulence factor and the host immune response:implications for therapeutic vaccination trend. Microbiology,2003, 11(3):112-120.
73 Corthesy-Theulaz I, Porta N, Glauser M, Vaney AC, Haas R, Kraehenbuhl JP, Blum AL, Michetti P. Oral immunization with Helicobacter pyloriurease B subunit as atreatment against helicobacter infection in mice [J]. Gastroenterology 1995,109(1): 115-119.
74 Coudron PE, Strstton CW. Factors affecting growth and susceptibility testing of helicobacter pylori in liquid media. J Clinical Microbiology,1995,4:1028-1030.
75 Cover TL, Blaser MJ. Humen serologic response to campykobacter pylori-cytotoxin-associated proteins. Gastroenterology,1989,96:A101-105.
76 Cuenca R, Blanellard TG. Czinn SJ, JG Nedrud, Monath TP, Lee CK, Redline RW. Therapeutic immunization against Helicobater mustelae in naturally infected ferrets. Gastroenterology,1996,110(6):1770-1775.
77 Czinn SJ. Nedrud JG. Oral immunization against helieobacter pylori. Infeet Immun, 1991.59(7):2359-2363.
78 Del Giudice G. Towards the development of vaccines against Helicobacter pylori: status and issues. Current Opinion in Investigational Drugs,2001,2:40-44
79 Delchier JC, Lamarque D, Levy M, Tkoub EM, Copie-Bergman C, Deforges L, Chaumette MT, Haioun C. Helicobacter pylori and gastric lymphoma:high seroprevalence of CagA in diffuselarge B-cell lymphoma but not in low-grade lymphoma of mucosa-associatedlymphoid tissue type. Am J Gastroenterol,2001,96: 2324-2328.
80 Del Giudice G. Towards the development of vaccines against Helicobacter pylori: status and issues. Current Opinion in Investigational Drugs,2001,2:40-44
81 Del Giudice G, Covacci A, Telford JL, Montecucco C, Rappuoli R. The design of vaccines against Helicobacter pylori and their development [J]. Annu Rev Immunol, 2001,19(1):523-563.
82 Delchier JC, Lamarque D, Levy M, Tkoub EM, Copie-Bergman C, Deforges L, Chaumette MT, Haioun C. Helicobacter pylori and gastric lymphoma:high seroprevalence of CagA in diffuselarge B-cell lymphoma but not in low-grade lymphoma of mucosa-associatedlymphoid tissue type. Am J Gastroenterol,2001,96: 2324-2328.
83 Donahue JP, Peek RM, Van Doom LJ, Thompson SA, Xu Q, Blaser MJ, Miller GG. Analysis of iceAl transcription in Helicobacter pylori [J]. Helicobacter,2000, 5(1):1-12.
84 Eaton KA, Gilbert JV, Joyce EA, Wanken AE, Thevenot T, Baker P, Plaut A, Wright A. In vivo complementation of ureB restores the ability of Helicobacter pylori to colonize [J]. Infect Immun,2002,70(2):771-778.
85 Ebel GD, Dupuis AP 2nd, Nicholas D, Young D, Maffei J, Kramer LD. Detection by enzyme-linked immunosorbent assay of antibodies to West Nile virus in birds. Emerg Infect Dis.2002,8:979-82.
86 Emilia G, Longo G, Luppi M, Gandini G, Morselli M, Ferrara L, Amarri S, Cagossi K, Torelli G. Helicobacter pylori eradication can induce platelet recovery in idiopathic thrombocytopenic purpura. Blood,2001,97:812-814.
87 Fan X, Crowe SE, Behar S, Gunasena H, Ye G, Haeberle H, Van Houten N, Gourley WK, Ernst PB, Reyes VE. The effect of class II major histocompatibility complex expression on adherence of Helicobacter pylori and induction of apoptosis in gastric epithelial cells:a mechanismfor T helper cell type-1 mediated damage [J]. J Exp Med, 1998,187(10):1659-1669.
88 Figueiredo C,Van Doom LJ, Nogueira C, Soares JM, Pinho C, Figueira P, Quint WG, Carneiro F. Helicobacter pylori genotypes are associated with clinical outcome in Portuguese patients and show a high prevalence of infections with multiple strains. Scand J Gastroenterol,2001,36:128-135.
89 Figura N, Vindigni C, Covacci A, Presenti L, Burroni D, Vernillo R, Banducci T, Roviello F, Marrelli D, Biscontri M, Kristodhullu S, Gennari C, Vaira D. CagA positive and negative Helicobacter pylorisrain are simultaneously present in the stomach of most patients with non-ulcer dyspepsia relevance to histological damage. Gut,1998,42:772-778.
90 Fox JG, Dangler CA, Sager W, Borkowski R, Gliatto JM. Helicobacter mustelae associated gastric adenocarcinoma in ferrets [J]. Vet Pathol,1997,34 (3):225-229.
91 Galmiche A, Rassow J, Doye A, Cagnol S, Chambard JC, Contamin S, de Thillot V, Just I, Ricci V, Solcia E, Van Obberghen E, Boquet P. The N terminal 34 kDa fragment of Helicobacter pylori vacuolating cytotoxin targets mitochondria and induces cytochromec release [J]. EMBO J,2000,19(23):6361-6370.
92 Goodwin CS, John A. Transfer of Campylobacter pylori and Campylobacter mustelae to Helicobacter gen. nov as Helicobacter pylori comb, nov and Helicobacter mustelae comb, nov, Respectively. Int J Syst bacteriol,1989,5(11):397-405.
93 Gottwein JM, Blanchard TG, Targoni O S, Eisenberg JC,Zagorski BM, Redline RW, Nedrud JG, Tary-Lehmann M, Lehmann PV, Czinn SJ. Protective anti-Helicobacter immunity is induced with aluminum hydroxide or complete Freund's adjuvant by systemic immunization [J]. J Infect Dis,2001,184(3):308-314.
94 Han L; Mao DG; Zhang DK; Liang AX; Fang M; Moaeen-ud-Din M; Yang LG Development and evaluation of a novel DNA vaccine expressing inhibin alpha (1-32) fragment for improving the fertility in rats and sheep. Anim. Reprod. Sci.2008,109: 251-65.
95 Handa O, Naito Y, Yoshikawa T. CagA protein ofHelicobacter pyloni a hijacker of gastric epithelial cell signaling [J]. Biochem Pharmacol,2007,73(11):1697-1702.
96 Held M, Engstrand L, Hansson LE, Bergstrom R, Wadstrom T, Nyren O. Is the association between Helicobacter pylori and gastric cancer confined to CagA positive strains [J]. He licobacter,2004,9(3):271-277.
97 Hiyama T, Haruma K, Kitadai Y, Masuda H, Miyamoto M, Ito M, Kamada T, Tanaka S, Uemura N, Yoshihara M, Sumii K, Shimamoto F, Chayama K. Clinic opathological features of gastric mucosa-associated lymphoid tissue lymphoma:a comparison with diffuse large B-cell lymphoma without a mucosa-associated lymphoid tissue lymphoma component. J Gastroenterol Hepatol,2001,16:734-739.
98 Hou P, Tu ZX, Xu GM, Gong YF, Ti XH, Li ZS. Helicobacterpylori VacA genotypes and CagA status and their relationship to associated diseases. World J Gastroenterol, 2000,6:605-607.
99 Hu LT, Mobley HL. Purification and N-terminal analysise of urease from Helicobacter pylori. Infect Immun,1990,58(4):992-998.
100 Hurenkamp GJ, Grundmeijer HG, Van Der Ende A, Tytgat GN, Assendelft WJ, Van Der Hulst RW. Arrest of chronic acid suppressant drug use after successful Helicobacter pylori eradication in patients with peptic ulcer disease:a six-month follow-up study. Aliment Pharmacol Ther,2001,15:1047-1054.
101 Igarashi M, Kitada Y, Yoshiyama H, Takagi A, Miwa T, Koga Y. Ammonia an accelatator of tumor necrosis factor alpha-induced apoptosis of gastric epithelial cells in helicobacter pylori infection. Infection and Immunity,2001,69(2):816-821.
102 JeanMarie Houghton, Calin Stoicov, Sachiyo Nomura3, Arlin B. Rogers, Jane Carlson, Hanchen Li, Xun Cai, James G. Fox, James R. Goldenring and Timothy C. Gastric cancer originating from bone marrow-derived cells. Science,2004,306: 1568-1571.
103 Jiang Z, Tao XH, Huang AL, Wang PL. A study of recombinant protective H. pylori antigens [J]. World J Gastroenterol,2002,8(2):308-311.
104 Jones NL, Shannon PT, Cutz E, Yeger H, Sherman PM. Increase in proliferation and apoptosis of gastric epithelial cells early in the natural history of Helicobacter pylori infection [J]. Am J Pathol,1997,51(6):1695-1703.
105 Jones NL, Sherman PM. Helicobacter pylori-epithelial cell interactions:from adhesion to apoptosis [J]. Can J Gastroenterol,1999,13 (7):563-566.
106 Karita M, Li Q, Cantero D, Okita K. Establishment of a small animal model for human Helicobacter pylori infection using germ-free mouse [J]. Am J Gastroenterol, 1994,89(2):208-213.
107 Kate V, Ananthakrishnan N, Badrinath S. Effect of Helicobacter pylori eradication on the ulcer recurrence rate after simple closure of perforated duodenal ulcer: retrospective and prospective randomized controlled studies. Br J Surg.2001,88: 1054-1058.
108 Kidd M, Irvin MM. "A century ofHelicobacter pylori". Digestion,1998,59 (1):1-15.
109Kidd M, Peek RM, Lastovica AJ, Israel DA, Kummer AF, Louw JA. Analysis of iceA genotypes in South African Helicobacter pylori strains and relationship to clinically significant disease [J]. Gut,2001,49(5):629-635.
110 Kleanthous H, Myers G, Georgakopoulos K, Tibbitts T, Ingrasia JW, Gray HL, Ding RU, Zhang ZZ, Lei W, Nichols R, Lee CK, Ermak TH, Monath TP. Rectal and intranasal immunizations with recombinant urease induce distinct local and serum immune responses in mice and protect against Helicobacter pylori infection. Infect Immune.1998,66:2879-2886.
111 Koehler CI, Mues MB, Dienes H P, Kriegsmann J, Schirmacher P, Odenthal M. Helicobacter pylori genotyping in gastric adenocarcinoma and MALT lymphoma by multip lex PCR analyses of paraffin wax embedded tissues [J]. J Clin Pathol:Mol Pathol,2003,56(1):36-42.
112 Koesling J, Lucas B, Develioglou L, Aebischer T, Meyer TF. Vaccination of mice with live recombinant Salmonella typhimurium aroA against H. pylori:parameters associated with prophylactic and therapeutic vaccine efficacy. Vaccine 2001,20: 413-420.
113 Kohda K,Tanaka K, Aiba Y, Yasuda M, Miwa T, Koga Y. Role of apoptosis induced by Helicobacter pylori in fection in the development of duodenal ulcer [J]. Gut,1999, 44 (4):456-462.
114 Konno M, Muraoka S, Takahashi M, Imai T. Iron-deficiency anemia associated with Helicobacter pylori gastritis. J Pediatr Gastroenterol Nutr,2000,31:52-56.
115 Kotloff KL, Sztein MB, Wasserman SS, Losonsky GA, DiLorenzo SC, Walker RI. Safety and immunogenicity of oral inactivated whole-cell Helicobacter pylori vaccine with adjuvant among volunteers with or without subclinical infection. Infect Immun. 2001,69:3581-3590.
116 Krakowka S, Eaton KA, Leunk RD. Antimicrobial therapies for Helicobacter pylori infection in gnotobiotic piglets [J]. Antimicrob Agents Chemother,1998,42(7): 1549-1554.
117 Labigne A, Cussac V, Courcoux P. Shuttle cloning and nuleotide seguences of Helicobacter pylori genes responsible for urease activity[J]. JBacterlol,1991; 173 (6):1920-1931.
118 Lahaie RG, Gaudreau C. Helicobacter pylori antibiotic resistance:trends over time, Can. J. Gastroenterol,2000,14:895-899.
119Lee A, Fox JG, Otto G, Murphy J. A small animal model of human Helicobacter pylori active chronic gastritis [J]. Gastroenterology,1990,99(5):1315-1323.
120 Lembo A, Caradonna L, Magrone T, Mastronardi ML, Caccavo D, Jirillo E, Amati L. Helicobacter pylori infection, immune response and vaccination. Curr Drug Targets Immune Endocr Metabol Disord,2001,1(3):199-208.
121Leonarda YM, Boisseson MR, Bert P, Dalencon F, Dellacherie E. Hydrophobically modified alginate hydrogels as protein carriers with specific controlled release properties. J Control Release,2004,98(3):395-405.
122 Li MF, Li Z, Ma AY, Zhao JH, Sun JX, Yu SZ, Wu XP. Cloning, expression and immunogenicrity of Hp UreB gene. Shijie Huaren Xiaohua Zazhi,1999,7:596-600.
123 Liao W, Chen M, Zhu S. Construction of attenuated Salmonella typhimurium vaccine strain expressing Helicobacter pylori catalase and observation on its protective immunity. Zhonghua Yixue Zazhi,2001,81:613-616.
124 Liu XF, Hu JL, Zhang Xia and Fan DM. Oral immunization of mice with attenuated Salmonella typhimurium expressing Helicobacter pylori urease B subunit. Chinese Medical Journal,2002,115(10):1513-1516.
125 Man X, Wu B, Luo Y, Yu T, Zhao Z, Xu Y, Guo A, Chen H. Construction of attenuated Salmonella choleraesuis vaccine strain expressing recombinant antigen of Shiga-like toxin Escherichia coli. Wei Sheng Wu Xue Bao.2009,49(4):518-523.
126 Marcetti M, Rossi M, Giannelli V, Giuliani MM, Pizza M, Censini S, Covacci A, Massari P, Pagliaccia C, Manetti R, Telford JL, Douce G, Dougan G, Rappuoli R,Ghiara P. Protection against Helicobacter pylori infection in mice by intragastric vaccination with H. pylori antigens is achieved using a nontoxic mutant of E.coli heat-labile enterotoxin (LT) as adjuvant [J]. Vaccine,1998,16(1):33-38.
127 Marshall BJ. Helicobacter pylori. Am J Gastroenterol,1994,89(8):116-118.
128 Marshall, Barry. "The discovery thatHelicobacter pylori, a spiral bacterium, caused peptic ulcer disease". In Barry J. Marshall. Helicobacter pioneers:firsthand accounts from the scientists who discovered helicobacters,1892-1982. Oxford:Blackwell, 2002:165-202.
129 Mattson A, Quiding-Jarbrink M, Ahlsedt I. Helicobacter pylori specific B-cells in gastric mucosa. Gut,1996,39:A42.
130 Matz-Rensing K, Kunz E, Kraft C, Lorenzen D, Suerbaum S, Kaup FJ. Experimental Helicobacter pylori infection of rhesus macaques (Macaca mulatta) [J]. Int J Med Microbiol,2001,291(1):33-43.
131 Meijer BC, Thijs JC, Kleibeuker JH, van Zwet AA, Berrelkamp RJ. Evaluation of eight enzyme immunoassays for detection of immunoglobulin G against Helicobacter pylori. J Clin Microbiol,1997,35(1):292-294.
132 Michetti P, Corthesy-Theμlaz I. Immunization of BALB/c mice against Helicobacter felis infection with Helicobacter pylori urease [J]. Gastroenterology,1994,10(4): 1002-11.
133 Michetti P,Kreiss C, Kotloff KL, Porta N, Blanco JL, Bachmann D, Herranz M, Saldinger PF, Corthesy-Theulaz I, Losonsky G, Nichols R, Simon J, Stolte M,Ackerman S, Monath TP, Blum AL.. Oral immunization with urease and escherichia coli heatlabile enterotoxin is safe and immunogenic in Helicobacter pylori-infected adults. Gastroenterology,1999,116:804-812.
134 Michetti P. Vaccine against Helicobacter pylori:Fact or fiction? [Leading article] [J]. Gmt,1997; 41 (6):728-730.
135 Mobley HLT, Cortesia MJ, Rosenthal LE, Jones BD. Characterization of urease from CamPylobacter Pylori. J Clin Microbiol,1988,26:831-836.
136 Mobley HLT, Island MD, Hausniger RP. Molecular biology of microbial urease. Micorbiol Rev,1995,59:451-480.
137Morgner A, Miehlke S, Fischbach W, Schmitt W, Muller-Hermelink H, Greiner A, Thiede C, Schetelig J, Neubauer A, Stolte M, Ehninger G, Bayerdorffer E. Complete remission of primary high-grade B-cell gastric lymphoma after cure of Helicobacter pylori infection. J Clin Oncol,2001,19:2041-2048.
138 Mukhopadhyay P. Gastic cancer and Lymphoma. In:Westblom TU, Czinn SJ, Nedrud JG, eds. Curr Top Microbiol Immunol.Berlin:Springer Verlag,1999,57-69.
139 Nagata S. Apoptosis by death factor [J]. Cell,1997,88 (3):355-365.
140 Naito M, YamazakiT, Tsutsumi R, et al. Influence ofEPIYA repeat polymorphism on the phosphorylation dependent biological activity of Helicobacter pylori CagA [J]. Gastroenterology,2006,130(4):1181-1190.
141 Naito M, Yamazaki T, Tsutsumi R, Higashi H, Onoe K, Yamazaki S, Azuma T, Hatakeyama M. Influence ofEPIYA repeat polymorphism on the phosphorylation dependent biological activity of Helicobacter pylori CagA [J]. Gastroenterology, 2006,130(4):1181-1190.
142 Naito Y, Yoshikawa T, Fujii T, Boku Y, Yagi N, Dao S, Yoshida N, Kondo M, Matsui H, Ohtani-Fujita N, Sakai T. Monochloramine-induced cell growth inhibition and apoptosis in a rat gastric mucosal cell line [J]. J Clin G astroenterol,1997,25 (Suppl 1):S179-S185.
143 Nakamura S, Matsumoto T, Suekane H, Takeshita M, Hizawa K, Kawasaki M, Yao T, Tsuneyoshi M, Iida M, Fujishima M. Predictive value of endoscopic ultrasonography for regression of gastric low grade and high grade MALT lymphomas after eradication of Helicobacter pylori. Gut,2001,48:454-460.
144 Nakayama M, Hisatsune J,Yamasaki E, Isomoto H, Kurazono H, Hatakeyama M, Azuma T, Yamaoka Y, Yahiro K, Moss J, Hirayama T. Helicobacter pylori Vac A induced inhibition of GSK3 through the PI3K/Akt signaling pathway [J]. J Biol Chem,2009,284 (3):1612-1619.
145 Nakamura S, Matsumoto T, Suekane H, Takeshita M, Hizawa K, Kawasaki M, Yao T, Tsuneyoshi M, Iida M, Fujishima M. Predictive value of endoscopic ultrasonography for regression of gastric low grade and high grade MALT lymphomas after eradication of Helicobacter pylori. Gut,2001,48:454-460.
146 Nomura A, Stemmerman GN, Chyou pH. Helicobacter pylori infection and gastric carcinoma in a population of Japanese-Americans in Hawaii. N Engl J Med,1991, 325:1132-1136.
147 Novak MJ, Smythies LE, McPherson SA, Smith PD, Morrow CD. Poliovirus replicons encoding the B subunit of Helicobacter pylori urease elicit a Thl associated immune response [J]. Vaccine,1999,17(19):2384-2391.
148 Pappo J, ThomasWD, Kabok Z, Taylor NS, Murphy JC, Fox JG Effect of oral immunization with recombinant urease on murine Helicobacter felis Gastritis [J]. Infect Immun,1995,63(4):1246-1252.
149 Parkinson AJ, Gold BD, Bulkow L, Wainwright RB, Swaminathan B, Khanna B, Petersen KM, Fitzgerald MA. High prevalence of Helicobacter pylori in the Alaska native population and association with low serum ferritin levels in young adults. Clin Diagn Lab Immunol,2000,7:885-888.
150 Parsonnet J, Friedman GD, Vandersteen DP, Chang Y, Vogelman JH, Orentreich N, Sibley RK. Helicobacter pylori infection and the risk of gastric carcinoma [J].N EngJ Med,1991,325(16):1127-1131.
151 Parsonnet J, Hansen S, Rodrignez L, Gelb AB, Warnke RA, Jellum E, Orentreich N, Vogelman JH, Friedman GD. Helicobacter pyloriin-fection and gastric lymphoma [J]. N Eng J Med,1994,330(18):1267-1271.
152 Peek RM Jr, Thompson SA, Donahue JP, Tham KT, Atherton JC, Blaser MJ, Miller GG. Adherence to gastric epithelial cells induces expression of a Helicobacter pylori gene, iceA, that is associated with clinical outcome [J]. Proc Assoc Am Physicians, 1998,110 (6):531-544.
153 Peter S, Beglinger C. Helicobacter Hylori and gastric cancer:the causal relationship. Digestion,2007,75(1):25-35.
154 Peterson WL. Helicobacter pylori and peptic ulcer diseases [J].N Eng J Med,1991, 324(15):1043-1047.
155 Piotrowski J, Piotrowski E, Skrodzka D, Slomiany A, Slomiany BL. Induction of acute gastritis and epithelial apoptosis by Helicobacter pylori lipopolysaccharide [J]. Scand J Gastroenterol,1997,32 (3):203-211.
156 PoutahidisT, Tsangaris T, Kanakoudis Q Vlemmas I, Iliadis N, Sofianou D. Helicobacter pylori induced gastritis in experimentally infected conventional piglets [J]. Vet Pathol,2001,38(6):667-678.
157 Qiao HW, Sun JF, Han WY, Li ZS, Yu XL, Tu CC. Salmonella choleraesuis C500 delivering DNA immunization against classical swine fever virus. Chin. J.of Biotech. 2005,21(6):865-870.
158 Quan J, Fan XG. Progress in experimental research of Helicobacter pylori infection and gastric carcinoma. Shijie Huaren Xiaohua Zazhi,1999,7:1068-1069.
159 Raghavan S, Hjulstrom M, Holmgren J, Svennerholm AM. Protection against experimental Helicobacter pylori infection after immunization with inactivated H. pylori whole-cell vaccines [J]. Infect Immun,2002,70(11):6383-6388.
160 Ramirez C, Nacher J, Molowny A, Sanchez-Sanchez F, Irurzun A, Lopez-Garcia C. Photoperiod-temperature and neuroblast proliferation-migration in the adult lizard cortex. Neuroreport,1997,8:2337-2342.
161 Riedel S, Kraft M, Kucharzik T, Pauels HG, Tiemann M, Steinbiichel A, Domschke W, Lugering N. CD4+Thl-cells predominate in low-grade B-cell lymphoma of gastric mucosa-associated lymphoid tissue (MALT type). Scandinavian Journal of Gastroenterology,2001,36(11):1198-1203.
162 Saldinger PF, Porta N, Launois P, Louis JA, Waanders GA, Bouzourene H, Michetti P, Blum AL, Corthesy-Theulaz IE. Immunization of Balb/c mice with Helicobacter urease B induces a Thelper 2 response absent in Helicobacter infection. Gastroenterology,1998,115:891-897.
163 Satin B, Del Giudice G, Della Bianca V, Dusi S, Laudanna C, Tonello F, Kelleher D, Rappuoli R, Montecucco C, Rossi F. The neutrophil-activating protein (HP-NAP) of Helicobacter pylori is a protective antigen and a major virulence factor. J Exp Med 2000,191:1467-1476.
164 Saudi BA. The role of the putative virulence markers (cagA and vacA) of Helicobacter pylori in peptic ulcer disease [J]. Saudi Med J,2004,25(7):830-836.
165 Sheng T, Zhang JZ. Current situation on studies of Hp urease. Shijie Huaren Xiaohua Zazhi,1999,7:881-884.
166 Shirin H, Moss SF. Helicobacter pylori induced apoptosis [J]. Gut,1998,43 (4): 592-594.
167 Solnick JV, Canfield DR, Hansen LM, Torabian SZ. Immunization with recombinant Helicobacter pylori urease in specific-pathogen-free rhesus monkeys (Macaca mulatta). Infect Immun,2000,68:2560-2565.
168 Stills HF Jr, Hook RR Jr, Kinden DA. Isolation of Campylobaeter-like organism from healthy Syrian Hamsters (Mesocrieetus auratus). J of Clin Microbiol,1989,27(11): 2497-2501.
169 Suganuma M, Kurusu M, Okabe S, Sueoka N, Yoshida M, Wakatsuki Y, Fujiki H. Helicobacter pylori membrane protein:a new carcinogenic factor of Helicobacter pylori. Cancer Res.2001,61:6356-6359.
170 Sugiyama A, Maruta F, Ikeno T, Ishida K, Kawasaki S, Katsuyama T, Shimizu N, Tatematsu M. Helicobacter pylori infection enhances N-methyl-N-nitrosourea-induced stomach carcinogenesis in the Mongolian gerbil[J]. Cancer Res,1998,58(10):2067-2069.
171 Todoroki I, Joh T, Watanabe K, Miyashita M, Seno K, Nomura T,Ohara H, Yokoyama Y, Tochikubo K, Itoh M. Suppressive effects of DNA vaccines encoding heat shock protein on Helicobacter pylori-induced gastritis in mice [J]. Biochem Biophys Res Commun,2000,277(1):159-163.
172 Tsang KW, Lam WK, Kwok E, Chan KN, Hu WH, Ooi GC, Zheng L, Wong BC, Lam SK. Helicobacter pylori and upper gastrointestinal symptoms in bronchiectasis. Eur Respir J,1999,14:1345-1350.
173 Tsuji M, K awano S,Tsuji M, Ito T, Nagano K, Sasaki Y, Hayashi N, Fusamoto H, Kamada T. Cell kinetics of mucosal atrophy in rat stomach induced by long term administration of ammonia [J]. Gastroenterology,1993,104 (3):796-801.
174 Tsutsumi R, Takahashi A, AzumaT, Higashi H, Hatakeyama M. Focal adhesion kinase is a substrate and down stream effect or of SHP-2 complexed with Helicobacter pylori CagA [J]. Mol Cell Biol,2006,26(1):261-276.
175 Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, Taniyama K, Sasaki N, Schlemper RJ. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med.2001,345:784-789.
176 Wagner S, Beil W, Westermann J, Logan RP, Bock CT,Trautwein C, Bleck JS, Manns MP. Regulation of gastric epithelial cell growth by Helicobacter pylori: evidence for a major role of apoptosis [J]. Gastroenterology,1997,113(6): 1836-1847.
177 Wang HT, Li ZH, Yuan JP, Zhao W, Shi XD,Tong SQ, Guo XK. Effect of Helicobacter pylori Vac A on gene expression of gastric cancer cells [J]. World J Gastroenterol,2005,11(1):109-113.
178 Wang S, Li Y, Scarpellini G, Kong W, Shi H, Baek CH, Gunn B, Wanda SY, Roland KL, Zhang X, Senechal-Willis P, Curtiss R 3rd. Salmonella vaccine vectors displaying delayed antigen synthesis in vivo to enhance immunogenicity [J]. Infect Immun,2010,78 (90):3969-3680.
179 Warren, JR. Barry Marshall. "Unidentified curved bacilli on gastric epithelium in active chronic gastritis". Lancet 1,1983:1273-1275.
180 Warren, JR. "The discovery of Helicobacter pylori in Perth, Western Australia". In Barry J. Marshall. Helicobacter pioneers:firsthand accounts from the scientists who discovered helicobacters,1892-1982. Oxford:Blackwell,2002:151-164.
181 Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A, Feigner PL. Direct gene transfer into mouse muscle in vivo [J]. Science,1990,247(4949Ptl): 1465-1468.
182 Xu Can-Xia, Jia Yan, Yang Wen-Bin, Zou Hui-Fang, Wang Fen, Shen Shou Rong. Effect of Helicobacter pylori on Cell Gap Junction Ultrastructure of Gastric Epithelial Cells. Prog Biochem Biophys,2009,36(6):272-278.
183 Xu X, Husseiny MI, Goldwich A, Hensel M. Efficacy of intracellular activated promoters for generation of Salmonella- based vaccines [J]. Infect Immun,2010, 78(11):4828-4838.
184 Xue FB, Xu YY, Wan Y, Pan BR, Ren J, Fan DM. Association of H, pylori infection with gastric carcinoma:a Meta analysis. World J Gastroenterol,2001,7:801-804.
185 Yamaoka Y, Kudo T, Lu H, Casola A, Brasier AR, Graham DY. Role of interferon stimulated responsive element like element in interleukin 8 promoter in Helicobacter pylori infection [J]. Gastroenterology,2004,126(4):1030-1043.
186 Yamaoka Y, Kwon DH, Graham DY. A Mr 34000 proinflammatory outer membrane protein (oipA) ofHelicobacter pylori [J].Nat Acad Sci,2000,97(13):7533-7538.
187 Yang LG, Hu SC, Wei pH, Guo AZ. Enzyme Immunoassay Technology. Nanjing University Press, Nanjing (in Chinese):1998.
188 Yuan JP, Li T, Shi X D, Hu BY, Yang GZ,Tong SQ, Guo XK. Deletion of Helicobacter pylori vacuolating cytotoxin gene by introduction of directed mutagenesis [J]. World J Gastroenterology,2003,9(10):2251-2257.
189 Zambon CF, Basso D, Navaglia F, Germano G, Gallo N, Milazzo M, Greco E, Fogar P, Mazza S, Di Mario F, Basso G, Rugge M, Plebani M. Helicobacter pylori virulence genes and host IL 1RN and IL 1β genes interplay in favouring the development of peptic ulcer and intestinal metaplasia [J]. Cytokine,2002,18(5):242251.
190 Zevering Y, Jacob L, Meyer TF. Naturally acquired human immune responses against Helicobacter pylori and implications for vaccine development. Gut 1999,45: 465-474.
191 Zhao ZQ, Xue Y; Wu B; Tang XB; Hu RM; Xu YD; Guo AZ, Chen HC. Subcutaneous Vaccination with Attenuated Salmonella enterica Serovar Choleraesuis C500 Expressing Recombinant Filamentous Hemagglutinin and Pertactin Antigens Protects Mice against Fatal Infections with both S. enterica Serovar Choleraesuis and Bordetella bronchiseptica. Infection and Immunity,2008,6:2157-2163.
2 北京地区幽门螺杆菌多中心临床试验协作组.不同组合的三联疗法对幽门螺杆菌阳性十二指肠溃疡的疗效及1年随访研究.中华医学杂志,2004,84(14)：1161-1165.
3 边专,樊明文,杜民权,张平,陈文霞,王茜.变形链球菌Gtase高表达株免疫奶牛应用研究.口腔医学纵横杂志,1999,15(1)：1-3.
4 陈洁,陈星湖,王锦辉,朱森林.幽门螺杆菌疫苗接种小鼠产生免疫后胃炎的影响因素。世界华人消化杂志2006；14(23)：2275～2280
5 陈晶晶,杨昭徐,蒋秀高,张建中,梁丕霞.幽门螺杆菌全菌抗原与尿素酶纯化抗原ELISA检测在人群血清学诊断中的应用.中华流行病学杂志,1996,17(1)：4-6.
6 陈学军,严杰,毛亚飞,李立伟.浙江人群幽门螺杆菌CagA/VacA优势基因型和不同基因型混合感染的调查.中华流行病学杂志,2003(11)：1031-1035.
7 邓长生,杨艺.幽门螺杆菌对胃上皮细胞SGC-901凋亡的影响.中国病理生理杂志,2001,17(12)：1249-1251.
8 丁力。幽门螺杆菌基因克隆及表达。硕士论文,2005.
9 冯百岁,姚雪华,赵国强.幽门螺杆菌细胞毒素相关基因A绿色荧光蛋白真核表达载体的构建.中华医学杂志.2007,(8)：32-36.
10高东旗,李仕英,王庭桂.含抗幽门螺杆菌特异性抗体免疫牛奶的制备.医学动物防制,2005,1：1-2
11高原,邹全明,吴超.幽门螺杆菌napA基因克隆及高效表达与鉴定.中国人兽共患病学报,2006,22(9)：882-887.
12宫月华,袁媛.中国庄河胃癌高发区幽门螺杆菌毒力基因型菌株感染分布特征 [J].中华医学杂志,2006,86(6)：419-421.
13郭红,邹全明,赵晓曼,吴超,毛旭虎,文国义.人幽门螺杆菌热休克蛋白A基因的克隆、表达及初步应用.第三军医大学学报,2001,23(7)：786-789.
14黄昌炳,冯文达,薛民权,张绪基,杨少章,杨绍钧,窦荫梅,贾顺庚.仔猪副伤寒弱毒通气培养冻干苗口服免疫研究[J].中国农业科学,1981,6(1)：89-94.
15黄学勇,许汴利,段广才,范清堂,郗园林.幽门螺杆菌黏附素HpaA蛋白在大肠杆菌中表达及其免疫保护作用.中国人兽共患病学报,2010,26(6)：565-568.
16贾继辉,贾继龙,娄峥,黄谷良,林特夫.幽门螺杆菌L型分子生物字性状的研究.中华微生物学和免疫学杂志,1995,15(2)：95-98.
17康凯.仔猪副伤寒活疫苗[J].中国兽药杂志,2003,37(2)：49.
18兰春慧,张渊智,房殿春.幽门螺杆菌感染诱发蒙古沙鼠胃黏膜肠上皮化生和异型增生[J].解放军医学杂志,2003,28(11)：985-990。
19李仕英,时兰春,王缚鲲,张海谱.含抗幽门螺杆菌特异性抗体牛奶清除效果的动物实验研究.中华医院感染学杂志,2010,20(9)：1230-1232.
20李仕英,王苋,侯雨丰,高东旗,张海谱,赵伟,王宪灵,姚瑶,王庭桂.免疫球蛋白在胃液中对幽门螺杆菌的杀灭作用[J].中国人兽共患病杂志,2004,20(8)：719.
21梁爱心,冯细钢,韩丽,滑国华,桑雷,刘兴斌,刘耘,杨利国.新型生长抑素原核表达质粒的构建及表达鉴定.生物工程学报,2008,24(6)：995-998.
22廖文俊,陈旻湖,朱森林,陈洁,陈为,胡品津.表达幽门螺杆菌过氧化氢酶的减毒沙门氏菌疫苗株的构建及其免疫保护作用的观察,中华医学杂志,2001,10：613-616.
23刘淼,杨致邦,林珊珊,吴利先.幽门螺杆菌细胞空泡毒素基因毒性片段的克隆与表达.重庆医科大学学报,2003,6：720-723.
24刘庆春,韩梅娇,李鸿滨.胃癌与幽门螺杆菌cagA,hrgA基因相关性研究[J].现代生物学进展,2007(2)：261-263.
25刘文忠.幽门螺杆菌研究进展.上海：上海科学技术文献出版社,2001,309-328.
26卢世云,潘秀珍,彭孝伟,施作霖.幽门螺杆菌感染对胃癌细胞的动力学影响[J].世界华人消化杂志,1997,7：760-762.
27潘春留,闰雷,娜仁图娜拉,卿素珠,关伟军,马月辉.流式细胞术研究细胞凋亡的方法与技术.现代生物医学进展,2009,9(4)：790-793.
28庞莎莎,刘丽华.抗幽门螺杆菌免疫抗体口服液清除幽门螺杆菌临床观察.中国中医药信息杂志,1999,6(7)：44.
29乔文,胡家露,吴开春,彭道荣,孙怡群.幽门螺杆菌vacA基因型与胃癌及癌前病变的相关性[J].中华内科杂志,2000,39(11)：729-731.
30任莉,郭刚,邹全明.幽门螺杆菌基因组多态性的研究进展[J].医学研究生学报,2010,23(4)：408-411.
31孙红斌,许杨,熊勇华.特异性抗体对幽门螺杆菌抗原各组分中和作用的初探.第三届国际天然药与微生态学术研讨会论文集.呼合浩特：内蒙古大学出版社,2000： 28.
32谭宝.幽门螺杆菌相关性胃病保健型免疫乳制品制备的研究.硕士毕业论文：2007.
33王娟,王润.中国幽门螺杆菌感染流行病学杂志Mata分析.中华流行病学杂志,2003,24(6)：443-446.
34魏华,许杨,熊勇华.抗幽门螺杆菌牛初乳体外调理杀伤研究.中华微生物学和免疫学杂志.2002,22(2)：168-169.
35吴超,邹全明,郭红,张卫军,袁小澎,毛旭虎.幽门螺杆菌UreB与大肠杆菌LTB基因融合及表达的研究.中华微生物学和免疫学杂志,2002,22(2)：175-179.
36项兆英,Covaeei A, Telford JL, ACensini S, Bayeli PF, Figura N, Rappuoli R.一种新的幽门螺杆菌分类法—根据幽门螺杆菌毒力因子CagA和VacA的表达.中华消化杂志,1995,S1：5-8.
37徐华洲,石玉娥,刘改芳,崔艳,刘文泰,郝慧泉,李国川.抗幽门螺杆菌羊奶的制备及体内外对幽门螺杆菌作用的研究.中国人兽共患病杂志,2003,19(3)： 101-103.
38徐义辉,糜克永,龙焱华.幽门螺杆菌CagA基因探针的制备与临床应用.中华微生物学和免疫学杂志.1999年,3(19)：23-28.
39徐引弟,郭爱珍,刘维红,贾爱卿,陈焕春.猪霍乱沙门氏菌C500株△crp△asd缺失株平衡致死载体系统的构建及鉴定[J].生物工程学报,2006,22(3)：366-372.
40徐引弟,郭爱珍,刘维红,贾爱卿,陈焕春.绿荧光蛋白基因在猪霍乱沙门氏菌C500株asd-缺失株平衡致死载体系统中的表达[J].中国兽医学报,2007,27(4)：493-496.
41许杨,熊勇华,魏华,钟青萍,陈红兵,孙红斌.幽门螺杆菌全菌抗原对母鸡的免疫原性.中国生物制品学杂志,2000,13：147-150.
42阎小君,张沥,韩锋产,江梅,苏成芝.定量检测幽门螺杆菌细胞毒素相关蛋白基因A方法的建立.胃肠病学,1997,3：187-190.
43杨廷彬,尹学念主编.实用免疫学.长春：长春出版社,1994：87.
44杨艺,邓长生.幽门螺杆菌黏附于人胃黏膜的机制.国外医学.消化系疾病分册2000,20：79-82.
45袁小澎,邹全明,柏杨,杨瑁,郭鹰,张卫军,刘正祥.幽门螺杆菌尿素酶B亚单位功能片段的纯化及活性研究.南方医科大学学报,2007；27(7)：959-962.
46张彩凤,夏永华,韩宇,常廷民.幽门螺杆菌iceA基因型与胃黏膜病变的相关性[J].世界华人消化杂志,2008,16(20)：2312-2315.
47张和平,关红,李立民,骆承庠.初乳中低分子量部分的抗炎活性[J].中国乳品工业,2000,28(1)：23-25.
48张和平,李立民,程涛,骆承庠.利用超滤法从免疫初乳中分离乳抗体[J].中国乳品工业,1999,27(4)：3-6.
49张和平,殷文政,王和平,韩润林,李立民,孙天松.免疫乳及其制品研究[J].中国乳品工业,1997,25(5)：15-22.
50张和平,孙天竹,郭军,李立民.免疫初乳中1gG对小鼠腹泻的被动免疫保护[Z]. 哈尔滨：食品科技研究进展,中国畜产品加工研究会,1999：31-38.
51张世联,刘冉,王薇.牛幽门螺杆菌抗体中和菌体蛋白对Hela细胞的生长抑制作用.世界华人消化杂志,2005,15：1828-1833.
52张天哲,袁聚祥,徐应军,张铁民,范红敏,马立人,张小平.幽门螺杆菌免疫奶羊的免疫应答机制及其应用前景分析.卫生研究,2005,34(1)：82-84.
53赵战勤,徐引弟,吴斌,程相朝,李银聚,汤细彪,张春杰,陈焕春.猪霍乱沙门氏菌AasdC500株的生物学特性及作为活疫苗表达载体的应用.生物工程学报,2009,1：29-36.
54甄艳红,韩丽,梁爱心,王庆玲,杨利国.含抑制素重组质粒的减毒猪霍乱沙门氏菌C500遗传稳定性研究[J].生物技术通报,2009(S 1)：300-304.
55周燕,朱尤庆,黄梅芳,肖建群,邓长生.Hp-CagA抗体测定与消化性溃疡和慢性胃炎的关系.武汉大学学报(医学版),2001,22(4)：362-363.
56朱森林,陈旻湖,廖文俊,陈洁,胡品津.表达幽门螺杆菌UreB减毒鼠伤寒沙门氏菌对小鼠的免疫保护作用.中山医科大学学报,2001,22(6)：418-422.
57庄坤,张军,张玲霞,张沥,张建中.西安地区幽门螺杆菌iceAl、iceA2和babA2基因型与致病性的研究[J].细胞与分子免疫学志,2007,23(6)：520-522.
58庄小强,林三仁.幽门螺杆菌与胃癌的研究进展[J].世界华人消化杂志,2000,8：206-207.
59宗红,李建生,张金平,陈香宇,董子明.幽门螺杆菌对胃上皮细胞株GES-1凋亡及XIAP表达的影响.山东医药,2005,45(31)：11-12.
60邹全明,毛旭虎,郭刚,鲁东水,童文德,曾明,王斌,计国欣,朱凤才,李亮.口服重组幽门螺杆菌疫苗Ⅰ、Ⅱ期临床研究.中华医学会第七次全国消化病学术会议论文汇编(上册),2007：285-286.
61 Alm RA, Ling LS, Morr DT, King BL, Brown ED, Doig PC, Smith DR, Noonan B, Guild BC, deJonge BL, Carmel G, Tummino PJ, Caruso A, Uria-Nickelsen M,Mills DM, Ives C, Gibson R, Merberg D, Mills SD, Jiang Q, Taylor DE,Vovis GF, Trust TJ. Genomic sequence comparison of two unrelated isolates of the human gastric pathogen Helicobacter pylori [J]. Nature,1999,397(6715):176-180.
62 Ameiss K, Ashraf S, Kong W, Andrew Pekosz, Wai-Hong Wu, David Milich, Jean-Noel Billaud, Roy Curtiss. Delivery of woodchuck hepatitis virus-like particle presented influenza M2e by recombinant attenuated Salmonella displaying a delayed lysis phenotype[J]. Vaccine,2010,28(41):6704-6713.
63 Ando T, Wassenaar TM, Peek RM Jr, Aras RA, Tschumi AI, van Doom LJ, Kusugami K, Blaser MJ. A Helicobacter pylori restrition endonuclease replacing gene, hrgA is associated with gastric cancer in Asian strain [J]. Cancer Res,2002,62(8): 2385-2389.
64 Atherton JC, Peek RM, Tham KT, Cover TL, Blaser MJ. Clinical and pathological important of heterogeneity in vac A, the vacuolating cytotoxin gene of Helicobacter pylori [J]. Gastroenterology,1997,112 (1):92-99.
65 Backert S, Ziska E, Brinkmann V, Zimny-Arndt U, Fauconnier A, Jungblut PR, Naumann M, Meyer TF. Translocation of the Helicobacter pylori CagA protein in gastric epithelial cells by a type IV secretion apparatus.Cell Microbiol,2000,2: 155-164.
66 Bai Y. Study on the cloning, expression and the immunogenicity of Helicobacter pylori heat shock protein 60 gene [J].Di Yi Jun Yi Da Xue Xue Bao,2002,22(1):3-5.
67 Basso D, Zambon CF, Letley DP, Stranges A, Marchet A, Rhead JL, Schiavon S, Guariso G, Ceroti M, Nitti D, Rugge M, Plebani M, Atherton JC. Clinical relevance of Helicobacter pylori CagA and Vac A gene polymorphisms [J].Gastroenterology, 2008,135(1):91-99.
68 Bumann D, Metzger WG, Mansouri E, Palme O, Wendland M, Hurwitz R, Haas G, Aebischer T, von Specht BU, Meyer TF. Safety and immunogenicity of live recombinant Salmonella enterica serovar Typhi Ty21a expressing urease A and B from Helicobacter pylori in human volunteers.Vaccine,2001,20:845-852.
69 Casella G, Buda CA, Maisano R, Schiavo M, Perego D, Baldini V. Complete regression of primary gastric MALT-lymphoma after double eradication Helicobacter pylori therapy:role and importance of endoscopic ultrasonography. Anticancer Res, 2001,21(2B):1499-1502.
70 Chen GS, Sordillo EM, Ramey WG, Reidy J, Holt PR, Krajewski S, Reed JC, Blaser MJ, Moss SF. Apoptosis in gastric epithelial cell is induced by Helicobacter pylori and accompanied by increased expression of BAK [J]. Biochem Biophys Res Comm, 1997,239 (2):626-632.
71 Chen Y, Wang J, Shi L. In vitro study of the biological activities and immunogenicity of recombinant adhesin of Heliobacter pylori rHpaA. Zhonghua Yixue Zazhi.2000, 81:276-279.
72 Christian P, Nadia H, Perta V. Helicobacter pylori virulence factor and the host immune response:implications for therapeutic vaccination trend. Microbiology,2003, 11(3):112-120.
73 Corthesy-Theulaz I, Porta N, Glauser M, Vaney AC, Haas R, Kraehenbuhl JP, Blum AL, Michetti P. Oral immunization with Helicobacter pyloriurease B subunit as atreatment against helicobacter infection in mice [J]. Gastroenterology 1995,109(1): 115-119.
74 Coudron PE, Strstton CW. Factors affecting growth and susceptibility testing of helicobacter pylori in liquid media. J Clinical Microbiology,1995,4:1028-1030.
75 Cover TL, Blaser MJ. Humen serologic response to campykobacter pylori-cytotoxin-associated proteins. Gastroenterology,1989,96:A101-105.
76 Cuenca R, Blanellard TG. Czinn SJ, JG Nedrud, Monath TP, Lee CK, Redline RW. Therapeutic immunization against Helicobater mustelae in naturally infected ferrets. Gastroenterology,1996,110(6):1770-1775.
77 Czinn SJ. Nedrud JG. Oral immunization against helieobacter pylori. Infeet Immun, 1991.59(7):2359-2363.
78 Del Giudice G. Towards the development of vaccines against Helicobacter pylori: status and issues. Current Opinion in Investigational Drugs,2001,2:40-44
79 Delchier JC, Lamarque D, Levy M, Tkoub EM, Copie-Bergman C, Deforges L, Chaumette MT, Haioun C. Helicobacter pylori and gastric lymphoma:high seroprevalence of CagA in diffuselarge B-cell lymphoma but not in low-grade lymphoma of mucosa-associatedlymphoid tissue type. Am J Gastroenterol,2001,96: 2324-2328.
80 Del Giudice G. Towards the development of vaccines against Helicobacter pylori: status and issues. Current Opinion in Investigational Drugs,2001,2:40-44
81 Del Giudice G, Covacci A, Telford JL, Montecucco C, Rappuoli R. The design of vaccines against Helicobacter pylori and their development [J]. Annu Rev Immunol, 2001,19(1):523-563.
82 Delchier JC, Lamarque D, Levy M, Tkoub EM, Copie-Bergman C, Deforges L, Chaumette MT, Haioun C. Helicobacter pylori and gastric lymphoma:high seroprevalence of CagA in diffuselarge B-cell lymphoma but not in low-grade lymphoma of mucosa-associatedlymphoid tissue type. Am J Gastroenterol,2001,96: 2324-2328.
83 Donahue JP, Peek RM, Van Doom LJ, Thompson SA, Xu Q, Blaser MJ, Miller GG. Analysis of iceAl transcription in Helicobacter pylori [J]. Helicobacter,2000, 5(1):1-12.
84 Eaton KA, Gilbert JV, Joyce EA, Wanken AE, Thevenot T, Baker P, Plaut A, Wright A. In vivo complementation of ureB restores the ability of Helicobacter pylori to colonize [J]. Infect Immun,2002,70(2):771-778.
85 Ebel GD, Dupuis AP 2nd, Nicholas D, Young D, Maffei J, Kramer LD. Detection by enzyme-linked immunosorbent assay of antibodies to West Nile virus in birds. Emerg Infect Dis.2002,8:979-82.
86 Emilia G, Longo G, Luppi M, Gandini G, Morselli M, Ferrara L, Amarri S, Cagossi K, Torelli G. Helicobacter pylori eradication can induce platelet recovery in idiopathic thrombocytopenic purpura. Blood,2001,97:812-814.
87 Fan X, Crowe SE, Behar S, Gunasena H, Ye G, Haeberle H, Van Houten N, Gourley WK, Ernst PB, Reyes VE. The effect of class II major histocompatibility complex expression on adherence of Helicobacter pylori and induction of apoptosis in gastric epithelial cells:a mechanismfor T helper cell type-1 mediated damage [J]. J Exp Med, 1998,187(10):1659-1669.
88 Figueiredo C,Van Doom LJ, Nogueira C, Soares JM, Pinho C, Figueira P, Quint WG, Carneiro F. Helicobacter pylori genotypes are associated with clinical outcome in Portuguese patients and show a high prevalence of infections with multiple strains. Scand J Gastroenterol,2001,36:128-135.
89 Figura N, Vindigni C, Covacci A, Presenti L, Burroni D, Vernillo R, Banducci T, Roviello F, Marrelli D, Biscontri M, Kristodhullu S, Gennari C, Vaira D. CagA positive and negative Helicobacter pylorisrain are simultaneously present in the stomach of most patients with non-ulcer dyspepsia relevance to histological damage. Gut,1998,42:772-778.
90 Fox JG, Dangler CA, Sager W, Borkowski R, Gliatto JM. Helicobacter mustelae associated gastric adenocarcinoma in ferrets [J]. Vet Pathol,1997,34 (3):225-229.
91 Galmiche A, Rassow J, Doye A, Cagnol S, Chambard JC, Contamin S, de Thillot V, Just I, Ricci V, Solcia E, Van Obberghen E, Boquet P. The N terminal 34 kDa fragment of Helicobacter pylori vacuolating cytotoxin targets mitochondria and induces cytochromec release [J]. EMBO J,2000,19(23):6361-6370.
92 Goodwin CS, John A. Transfer of Campylobacter pylori and Campylobacter mustelae to Helicobacter gen. nov as Helicobacter pylori comb, nov and Helicobacter mustelae comb, nov, Respectively. Int J Syst bacteriol,1989,5(11):397-405.
93 Gottwein JM, Blanchard TG, Targoni O S, Eisenberg JC,Zagorski BM, Redline RW, Nedrud JG, Tary-Lehmann M, Lehmann PV, Czinn SJ. Protective anti-Helicobacter immunity is induced with aluminum hydroxide or complete Freund's adjuvant by systemic immunization [J]. J Infect Dis,2001,184(3):308-314.
94 Han L; Mao DG; Zhang DK; Liang AX; Fang M; Moaeen-ud-Din M; Yang LG Development and evaluation of a novel DNA vaccine expressing inhibin alpha (1-32) fragment for improving the fertility in rats and sheep. Anim. Reprod. Sci.2008,109: 251-65.
95 Handa O, Naito Y, Yoshikawa T. CagA protein ofHelicobacter pyloni a hijacker of gastric epithelial cell signaling [J]. Biochem Pharmacol,2007,73(11):1697-1702.
96 Held M, Engstrand L, Hansson LE, Bergstrom R, Wadstrom T, Nyren O. Is the association between Helicobacter pylori and gastric cancer confined to CagA positive strains [J]. He licobacter,2004,9(3):271-277.
97 Hiyama T, Haruma K, Kitadai Y, Masuda H, Miyamoto M, Ito M, Kamada T, Tanaka S, Uemura N, Yoshihara M, Sumii K, Shimamoto F, Chayama K. Clinic opathological features of gastric mucosa-associated lymphoid tissue lymphoma:a comparison with diffuse large B-cell lymphoma without a mucosa-associated lymphoid tissue lymphoma component. J Gastroenterol Hepatol,2001,16:734-739.
98 Hou P, Tu ZX, Xu GM, Gong YF, Ti XH, Li ZS. Helicobacterpylori VacA genotypes and CagA status and their relationship to associated diseases. World J Gastroenterol, 2000,6:605-607.
99 Hu LT, Mobley HL. Purification and N-terminal analysise of urease from Helicobacter pylori. Infect Immun,1990,58(4):992-998.
100 Hurenkamp GJ, Grundmeijer HG, Van Der Ende A, Tytgat GN, Assendelft WJ, Van Der Hulst RW. Arrest of chronic acid suppressant drug use after successful Helicobacter pylori eradication in patients with peptic ulcer disease:a six-month follow-up study. Aliment Pharmacol Ther,2001,15:1047-1054.
101 Igarashi M, Kitada Y, Yoshiyama H, Takagi A, Miwa T, Koga Y. Ammonia an accelatator of tumor necrosis factor alpha-induced apoptosis of gastric epithelial cells in helicobacter pylori infection. Infection and Immunity,2001,69(2):816-821.
102 JeanMarie Houghton, Calin Stoicov, Sachiyo Nomura3, Arlin B. Rogers, Jane Carlson, Hanchen Li, Xun Cai, James G. Fox, James R. Goldenring and Timothy C. Gastric cancer originating from bone marrow-derived cells. Science,2004,306: 1568-1571.
103 Jiang Z, Tao XH, Huang AL, Wang PL. A study of recombinant protective H. pylori antigens [J]. World J Gastroenterol,2002,8(2):308-311.
104 Jones NL, Shannon PT, Cutz E, Yeger H, Sherman PM. Increase in proliferation and apoptosis of gastric epithelial cells early in the natural history of Helicobacter pylori infection [J]. Am J Pathol,1997,51(6):1695-1703.
105 Jones NL, Sherman PM. Helicobacter pylori-epithelial cell interactions:from adhesion to apoptosis [J]. Can J Gastroenterol,1999,13 (7):563-566.
106 Karita M, Li Q, Cantero D, Okita K. Establishment of a small animal model for human Helicobacter pylori infection using germ-free mouse [J]. Am J Gastroenterol, 1994,89(2):208-213.
107 Kate V, Ananthakrishnan N, Badrinath S. Effect of Helicobacter pylori eradication on the ulcer recurrence rate after simple closure of perforated duodenal ulcer: retrospective and prospective randomized controlled studies. Br J Surg.2001,88: 1054-1058.
108 Kidd M, Irvin MM. "A century ofHelicobacter pylori". Digestion,1998,59 (1):1-15.
109Kidd M, Peek RM, Lastovica AJ, Israel DA, Kummer AF, Louw JA. Analysis of iceA genotypes in South African Helicobacter pylori strains and relationship to clinically significant disease [J]. Gut,2001,49(5):629-635.
110 Kleanthous H, Myers G, Georgakopoulos K, Tibbitts T, Ingrasia JW, Gray HL, Ding RU, Zhang ZZ, Lei W, Nichols R, Lee CK, Ermak TH, Monath TP. Rectal and intranasal immunizations with recombinant urease induce distinct local and serum immune responses in mice and protect against Helicobacter pylori infection. Infect Immune.1998,66:2879-2886.
111 Koehler CI, Mues MB, Dienes H P, Kriegsmann J, Schirmacher P, Odenthal M. Helicobacter pylori genotyping in gastric adenocarcinoma and MALT lymphoma by multip lex PCR analyses of paraffin wax embedded tissues [J]. J Clin Pathol:Mol Pathol,2003,56(1):36-42.
112 Koesling J, Lucas B, Develioglou L, Aebischer T, Meyer TF. Vaccination of mice with live recombinant Salmonella typhimurium aroA against H. pylori:parameters associated with prophylactic and therapeutic vaccine efficacy. Vaccine 2001,20: 413-420.
113 Kohda K,Tanaka K, Aiba Y, Yasuda M, Miwa T, Koga Y. Role of apoptosis induced by Helicobacter pylori in fection in the development of duodenal ulcer [J]. Gut,1999, 44 (4):456-462.
114 Konno M, Muraoka S, Takahashi M, Imai T. Iron-deficiency anemia associated with Helicobacter pylori gastritis. J Pediatr Gastroenterol Nutr,2000,31:52-56.
115 Kotloff KL, Sztein MB, Wasserman SS, Losonsky GA, DiLorenzo SC, Walker RI. Safety and immunogenicity of oral inactivated whole-cell Helicobacter pylori vaccine with adjuvant among volunteers with or without subclinical infection. Infect Immun. 2001,69:3581-3590.
116 Krakowka S, Eaton KA, Leunk RD. Antimicrobial therapies for Helicobacter pylori infection in gnotobiotic piglets [J]. Antimicrob Agents Chemother,1998,42(7): 1549-1554.
117 Labigne A, Cussac V, Courcoux P. Shuttle cloning and nuleotide seguences of Helicobacter pylori genes responsible for urease activity[J]. JBacterlol,1991; 173 (6):1920-1931.
118 Lahaie RG, Gaudreau C. Helicobacter pylori antibiotic resistance:trends over time, Can. J. Gastroenterol,2000,14:895-899.
119Lee A, Fox JG, Otto G, Murphy J. A small animal model of human Helicobacter pylori active chronic gastritis [J]. Gastroenterology,1990,99(5):1315-1323.
120 Lembo A, Caradonna L, Magrone T, Mastronardi ML, Caccavo D, Jirillo E, Amati L. Helicobacter pylori infection, immune response and vaccination. Curr Drug Targets Immune Endocr Metabol Disord,2001,1(3):199-208.
121Leonarda YM, Boisseson MR, Bert P, Dalencon F, Dellacherie E. Hydrophobically modified alginate hydrogels as protein carriers with specific controlled release properties. J Control Release,2004,98(3):395-405.
122 Li MF, Li Z, Ma AY, Zhao JH, Sun JX, Yu SZ, Wu XP. Cloning, expression and immunogenicrity of Hp UreB gene. Shijie Huaren Xiaohua Zazhi,1999,7:596-600.
123 Liao W, Chen M, Zhu S. Construction of attenuated Salmonella typhimurium vaccine strain expressing Helicobacter pylori catalase and observation on its protective immunity. Zhonghua Yixue Zazhi,2001,81:613-616.
124 Liu XF, Hu JL, Zhang Xia and Fan DM. Oral immunization of mice with attenuated Salmonella typhimurium expressing Helicobacter pylori urease B subunit. Chinese Medical Journal,2002,115(10):1513-1516.
125 Man X, Wu B, Luo Y, Yu T, Zhao Z, Xu Y, Guo A, Chen H. Construction of attenuated Salmonella choleraesuis vaccine strain expressing recombinant antigen of Shiga-like toxin Escherichia coli. Wei Sheng Wu Xue Bao.2009,49(4):518-523.
126 Marcetti M, Rossi M, Giannelli V, Giuliani MM, Pizza M, Censini S, Covacci A, Massari P, Pagliaccia C, Manetti R, Telford JL, Douce G, Dougan G, Rappuoli R,Ghiara P. Protection against Helicobacter pylori infection in mice by intragastric vaccination with H. pylori antigens is achieved using a nontoxic mutant of E.coli heat-labile enterotoxin (LT) as adjuvant [J]. Vaccine,1998,16(1):33-38.
127 Marshall BJ. Helicobacter pylori. Am J Gastroenterol,1994,89(8):116-118.
128 Marshall, Barry. "The discovery thatHelicobacter pylori, a spiral bacterium, caused peptic ulcer disease". In Barry J. Marshall. Helicobacter pioneers:firsthand accounts from the scientists who discovered helicobacters,1892-1982. Oxford:Blackwell, 2002:165-202.
129 Mattson A, Quiding-Jarbrink M, Ahlsedt I. Helicobacter pylori specific B-cells in gastric mucosa. Gut,1996,39:A42.
130 Matz-Rensing K, Kunz E, Kraft C, Lorenzen D, Suerbaum S, Kaup FJ. Experimental Helicobacter pylori infection of rhesus macaques (Macaca mulatta) [J]. Int J Med Microbiol,2001,291(1):33-43.
131 Meijer BC, Thijs JC, Kleibeuker JH, van Zwet AA, Berrelkamp RJ. Evaluation of eight enzyme immunoassays for detection of immunoglobulin G against Helicobacter pylori. J Clin Microbiol,1997,35(1):292-294.
132 Michetti P, Corthesy-Theμlaz I. Immunization of BALB/c mice against Helicobacter felis infection with Helicobacter pylori urease [J]. Gastroenterology,1994,10(4): 1002-11.
133 Michetti P,Kreiss C, Kotloff KL, Porta N, Blanco JL, Bachmann D, Herranz M, Saldinger PF, Corthesy-Theulaz I, Losonsky G, Nichols R, Simon J, Stolte M,Ackerman S, Monath TP, Blum AL.. Oral immunization with urease and escherichia coli heatlabile enterotoxin is safe and immunogenic in Helicobacter pylori-infected adults. Gastroenterology,1999,116:804-812.
134 Michetti P. Vaccine against Helicobacter pylori:Fact or fiction? [Leading article] [J]. Gmt,1997; 41 (6):728-730.
135 Mobley HLT, Cortesia MJ, Rosenthal LE, Jones BD. Characterization of urease from CamPylobacter Pylori. J Clin Microbiol,1988,26:831-836.
136 Mobley HLT, Island MD, Hausniger RP. Molecular biology of microbial urease. Micorbiol Rev,1995,59:451-480.
137Morgner A, Miehlke S, Fischbach W, Schmitt W, Muller-Hermelink H, Greiner A, Thiede C, Schetelig J, Neubauer A, Stolte M, Ehninger G, Bayerdorffer E. Complete remission of primary high-grade B-cell gastric lymphoma after cure of Helicobacter pylori infection. J Clin Oncol,2001,19:2041-2048.
138 Mukhopadhyay P. Gastic cancer and Lymphoma. In:Westblom TU, Czinn SJ, Nedrud JG, eds. Curr Top Microbiol Immunol.Berlin:Springer Verlag,1999,57-69.
139 Nagata S. Apoptosis by death factor [J]. Cell,1997,88 (3):355-365.
140 Naito M, YamazakiT, Tsutsumi R, et al. Influence ofEPIYA repeat polymorphism on the phosphorylation dependent biological activity of Helicobacter pylori CagA [J]. Gastroenterology,2006,130(4):1181-1190.
141 Naito M, Yamazaki T, Tsutsumi R, Higashi H, Onoe K, Yamazaki S, Azuma T, Hatakeyama M. Influence ofEPIYA repeat polymorphism on the phosphorylation dependent biological activity of Helicobacter pylori CagA [J]. Gastroenterology, 2006,130(4):1181-1190.
142 Naito Y, Yoshikawa T, Fujii T, Boku Y, Yagi N, Dao S, Yoshida N, Kondo M, Matsui H, Ohtani-Fujita N, Sakai T. Monochloramine-induced cell growth inhibition and apoptosis in a rat gastric mucosal cell line [J]. J Clin G astroenterol,1997,25 (Suppl 1):S179-S185.
143 Nakamura S, Matsumoto T, Suekane H, Takeshita M, Hizawa K, Kawasaki M, Yao T, Tsuneyoshi M, Iida M, Fujishima M. Predictive value of endoscopic ultrasonography for regression of gastric low grade and high grade MALT lymphomas after eradication of Helicobacter pylori. Gut,2001,48:454-460.
144 Nakayama M, Hisatsune J,Yamasaki E, Isomoto H, Kurazono H, Hatakeyama M, Azuma T, Yamaoka Y, Yahiro K, Moss J, Hirayama T. Helicobacter pylori Vac A induced inhibition of GSK3 through the PI3K/Akt signaling pathway [J]. J Biol Chem,2009,284 (3):1612-1619.
145 Nakamura S, Matsumoto T, Suekane H, Takeshita M, Hizawa K, Kawasaki M, Yao T, Tsuneyoshi M, Iida M, Fujishima M. Predictive value of endoscopic ultrasonography for regression of gastric low grade and high grade MALT lymphomas after eradication of Helicobacter pylori. Gut,2001,48:454-460.
146 Nomura A, Stemmerman GN, Chyou pH. Helicobacter pylori infection and gastric carcinoma in a population of Japanese-Americans in Hawaii. N Engl J Med,1991, 325:1132-1136.
147 Novak MJ, Smythies LE, McPherson SA, Smith PD, Morrow CD. Poliovirus replicons encoding the B subunit of Helicobacter pylori urease elicit a Thl associated immune response [J]. Vaccine,1999,17(19):2384-2391.
148 Pappo J, ThomasWD, Kabok Z, Taylor NS, Murphy JC, Fox JG Effect of oral immunization with recombinant urease on murine Helicobacter felis Gastritis [J]. Infect Immun,1995,63(4):1246-1252.
149 Parkinson AJ, Gold BD, Bulkow L, Wainwright RB, Swaminathan B, Khanna B, Petersen KM, Fitzgerald MA. High prevalence of Helicobacter pylori in the Alaska native population and association with low serum ferritin levels in young adults. Clin Diagn Lab Immunol,2000,7:885-888.
150 Parsonnet J, Friedman GD, Vandersteen DP, Chang Y, Vogelman JH, Orentreich N, Sibley RK. Helicobacter pylori infection and the risk of gastric carcinoma [J].N EngJ Med,1991,325(16):1127-1131.
151 Parsonnet J, Hansen S, Rodrignez L, Gelb AB, Warnke RA, Jellum E, Orentreich N, Vogelman JH, Friedman GD. Helicobacter pyloriin-fection and gastric lymphoma [J]. N Eng J Med,1994,330(18):1267-1271.
152 Peek RM Jr, Thompson SA, Donahue JP, Tham KT, Atherton JC, Blaser MJ, Miller GG. Adherence to gastric epithelial cells induces expression of a Helicobacter pylori gene, iceA, that is associated with clinical outcome [J]. Proc Assoc Am Physicians, 1998,110 (6):531-544.
153 Peter S, Beglinger C. Helicobacter Hylori and gastric cancer:the causal relationship. Digestion,2007,75(1):25-35.
154 Peterson WL. Helicobacter pylori and peptic ulcer diseases [J].N Eng J Med,1991, 324(15):1043-1047.
155 Piotrowski J, Piotrowski E, Skrodzka D, Slomiany A, Slomiany BL. Induction of acute gastritis and epithelial apoptosis by Helicobacter pylori lipopolysaccharide [J]. Scand J Gastroenterol,1997,32 (3):203-211.
156 PoutahidisT, Tsangaris T, Kanakoudis Q Vlemmas I, Iliadis N, Sofianou D. Helicobacter pylori induced gastritis in experimentally infected conventional piglets [J]. Vet Pathol,2001,38(6):667-678.
157 Qiao HW, Sun JF, Han WY, Li ZS, Yu XL, Tu CC. Salmonella choleraesuis C500 delivering DNA immunization against classical swine fever virus. Chin. J.of Biotech. 2005,21(6):865-870.
158 Quan J, Fan XG. Progress in experimental research of Helicobacter pylori infection and gastric carcinoma. Shijie Huaren Xiaohua Zazhi,1999,7:1068-1069.
159 Raghavan S, Hjulstrom M, Holmgren J, Svennerholm AM. Protection against experimental Helicobacter pylori infection after immunization with inactivated H. pylori whole-cell vaccines [J]. Infect Immun,2002,70(11):6383-6388.
160 Ramirez C, Nacher J, Molowny A, Sanchez-Sanchez F, Irurzun A, Lopez-Garcia C. Photoperiod-temperature and neuroblast proliferation-migration in the adult lizard cortex. Neuroreport,1997,8:2337-2342.
161 Riedel S, Kraft M, Kucharzik T, Pauels HG, Tiemann M, Steinbiichel A, Domschke W, Lugering N. CD4+Thl-cells predominate in low-grade B-cell lymphoma of gastric mucosa-associated lymphoid tissue (MALT type). Scandinavian Journal of Gastroenterology,2001,36(11):1198-1203.
162 Saldinger PF, Porta N, Launois P, Louis JA, Waanders GA, Bouzourene H, Michetti P, Blum AL, Corthesy-Theulaz IE. Immunization of Balb/c mice with Helicobacter urease B induces a Thelper 2 response absent in Helicobacter infection. Gastroenterology,1998,115:891-897.
163 Satin B, Del Giudice G, Della Bianca V, Dusi S, Laudanna C, Tonello F, Kelleher D, Rappuoli R, Montecucco C, Rossi F. The neutrophil-activating protein (HP-NAP) of Helicobacter pylori is a protective antigen and a major virulence factor. J Exp Med 2000,191:1467-1476.
164 Saudi BA. The role of the putative virulence markers (cagA and vacA) of Helicobacter pylori in peptic ulcer disease [J]. Saudi Med J,2004,25(7):830-836.
165 Sheng T, Zhang JZ. Current situation on studies of Hp urease. Shijie Huaren Xiaohua Zazhi,1999,7:881-884.
166 Shirin H, Moss SF. Helicobacter pylori induced apoptosis [J]. Gut,1998,43 (4): 592-594.
167 Solnick JV, Canfield DR, Hansen LM, Torabian SZ. Immunization with recombinant Helicobacter pylori urease in specific-pathogen-free rhesus monkeys (Macaca mulatta). Infect Immun,2000,68:2560-2565.
168 Stills HF Jr, Hook RR Jr, Kinden DA. Isolation of Campylobaeter-like organism from healthy Syrian Hamsters (Mesocrieetus auratus). J of Clin Microbiol,1989,27(11): 2497-2501.
169 Suganuma M, Kurusu M, Okabe S, Sueoka N, Yoshida M, Wakatsuki Y, Fujiki H. Helicobacter pylori membrane protein:a new carcinogenic factor of Helicobacter pylori. Cancer Res.2001,61:6356-6359.
170 Sugiyama A, Maruta F, Ikeno T, Ishida K, Kawasaki S, Katsuyama T, Shimizu N, Tatematsu M. Helicobacter pylori infection enhances N-methyl-N-nitrosourea-induced stomach carcinogenesis in the Mongolian gerbil[J]. Cancer Res,1998,58(10):2067-2069.
171 Todoroki I, Joh T, Watanabe K, Miyashita M, Seno K, Nomura T,Ohara H, Yokoyama Y, Tochikubo K, Itoh M. Suppressive effects of DNA vaccines encoding heat shock protein on Helicobacter pylori-induced gastritis in mice [J]. Biochem Biophys Res Commun,2000,277(1):159-163.
172 Tsang KW, Lam WK, Kwok E, Chan KN, Hu WH, Ooi GC, Zheng L, Wong BC, Lam SK. Helicobacter pylori and upper gastrointestinal symptoms in bronchiectasis. Eur Respir J,1999,14:1345-1350.
173 Tsuji M, K awano S,Tsuji M, Ito T, Nagano K, Sasaki Y, Hayashi N, Fusamoto H, Kamada T. Cell kinetics of mucosal atrophy in rat stomach induced by long term administration of ammonia [J]. Gastroenterology,1993,104 (3):796-801.
174 Tsutsumi R, Takahashi A, AzumaT, Higashi H, Hatakeyama M. Focal adhesion kinase is a substrate and down stream effect or of SHP-2 complexed with Helicobacter pylori CagA [J]. Mol Cell Biol,2006,26(1):261-276.
175 Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, Taniyama K, Sasaki N, Schlemper RJ. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med.2001,345:784-789.
176 Wagner S, Beil W, Westermann J, Logan RP, Bock CT,Trautwein C, Bleck JS, Manns MP. Regulation of gastric epithelial cell growth by Helicobacter pylori: evidence for a major role of apoptosis [J]. Gastroenterology,1997,113(6): 1836-1847.
177 Wang HT, Li ZH, Yuan JP, Zhao W, Shi XD,Tong SQ, Guo XK. Effect of Helicobacter pylori Vac A on gene expression of gastric cancer cells [J]. World J Gastroenterol,2005,11(1):109-113.
178 Wang S, Li Y, Scarpellini G, Kong W, Shi H, Baek CH, Gunn B, Wanda SY, Roland KL, Zhang X, Senechal-Willis P, Curtiss R 3rd. Salmonella vaccine vectors displaying delayed antigen synthesis in vivo to enhance immunogenicity [J]. Infect Immun,2010,78 (90):3969-3680.
179 Warren, JR. Barry Marshall. "Unidentified curved bacilli on gastric epithelium in active chronic gastritis". Lancet 1,1983:1273-1275.
180 Warren, JR. "The discovery of Helicobacter pylori in Perth, Western Australia". In Barry J. Marshall. Helicobacter pioneers:firsthand accounts from the scientists who discovered helicobacters,1892-1982. Oxford:Blackwell,2002:151-164.
181 Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A, Feigner PL. Direct gene transfer into mouse muscle in vivo [J]. Science,1990,247(4949Ptl): 1465-1468.
182 Xu Can-Xia, Jia Yan, Yang Wen-Bin, Zou Hui-Fang, Wang Fen, Shen Shou Rong. Effect of Helicobacter pylori on Cell Gap Junction Ultrastructure of Gastric Epithelial Cells. Prog Biochem Biophys,2009,36(6):272-278.
183 Xu X, Husseiny MI, Goldwich A, Hensel M. Efficacy of intracellular activated promoters for generation of Salmonella- based vaccines [J]. Infect Immun,2010, 78(11):4828-4838.
184 Xue FB, Xu YY, Wan Y, Pan BR, Ren J, Fan DM. Association of H, pylori infection with gastric carcinoma:a Meta analysis. World J Gastroenterol,2001,7:801-804.
185 Yamaoka Y, Kudo T, Lu H, Casola A, Brasier AR, Graham DY. Role of interferon stimulated responsive element like element in interleukin 8 promoter in Helicobacter pylori infection [J]. Gastroenterology,2004,126(4):1030-1043.
186 Yamaoka Y, Kwon DH, Graham DY. A Mr 34000 proinflammatory outer membrane protein (oipA) ofHelicobacter pylori [J].Nat Acad Sci,2000,97(13):7533-7538.
187 Yang LG, Hu SC, Wei pH, Guo AZ. Enzyme Immunoassay Technology. Nanjing University Press, Nanjing (in Chinese):1998.
188 Yuan JP, Li T, Shi X D, Hu BY, Yang GZ,Tong SQ, Guo XK. Deletion of Helicobacter pylori vacuolating cytotoxin gene by introduction of directed mutagenesis [J]. World J Gastroenterology,2003,9(10):2251-2257.
189 Zambon CF, Basso D, Navaglia F, Germano G, Gallo N, Milazzo M, Greco E, Fogar P, Mazza S, Di Mario F, Basso G, Rugge M, Plebani M. Helicobacter pylori virulence genes and host IL 1RN and IL 1β genes interplay in favouring the development of peptic ulcer and intestinal metaplasia [J]. Cytokine,2002,18(5):242251.
190 Zevering Y, Jacob L, Meyer TF. Naturally acquired human immune responses against Helicobacter pylori and implications for vaccine development. Gut 1999,45: 465-474.
191 Zhao ZQ, Xue Y; Wu B; Tang XB; Hu RM; Xu YD; Guo AZ, Chen HC. Subcutaneous Vaccination with Attenuated Salmonella enterica Serovar Choleraesuis C500 Expressing Recombinant Filamentous Hemagglutinin and Pertactin Antigens Protects Mice against Fatal Infections with both S. enterica Serovar Choleraesuis and Bordetella bronchiseptica. Infection and Immunity,2008,6:2157-2163.